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resumo 
 
 
Os atuais critérios clínicos de diagnóstico da doença de Alzheimer geralmente 
identificam a patologia apenas quando os pacientes já atingiram a fase de 
demência, ou seja, o estágio mais avançado da doença. Isto revela-se 
demasiado tarde para que qualquer tipo de terapêutica seja bem-sucedida e, 
consequentemente é necessário desenvolver uma metodologia de diagnóstico 
que permita um reconhecimento mais precoce da doença. Desta forma, é 
preciso adotar diferentes abordagens para a descoberta de novos 
biomarcadores para a doença de Alzheimer, tais como a utilização de técnicas 
de metabolómica (ex. FTIR). O potencial do FTIR no campo clínico recebeu 
recentemente particular atenção, sendo que esta técnica utiliza as frequências 
de vibração das moléculas presentes na amostra analisada para produzir uma 
“impressão digital” metabólica, a qual é específica para cada amostra. 
Esta dissertação tem como objetivo a identificação de potenciais alterações 
bioquímicas que possam estar relacionadas com demência, tornando possível 
a distinção entre grupos controlo e de doentes no seio do conjunto de amostras 
de plasma analisadas. A utilização de amostras de plasma torna o processo 
minimamente invasivo, de entre outras vantagens clínicas. Para além da colheita 
das amostras de sangue utilizadas neste projeto, os voluntários foram 
submetidos a uma avaliação cognitiva através da realização do MMSE e do 
CDR, com outra informação clínica relevante a ser também recolhida. Todas as 
amostras analisadas foram emparelhadas de acordo com a idade e o sexo.  
Para uma melhor distinção entre amostras controlo e de doentes foi aplicada a 
metodologia de PCA aos dados dos espectros obtidos em regiões específicas, 
nomeadamente em 3500-2700 cm-1, 1700-1400 cm-1, e 1200-900 cm-1. Isto 
permitiu identificar as principais alterações patológicas que ocorrem a nível 
bioquímico durante o desenvolvimento da doença neurodegenerativa. Na 
primeira região espectral referida, as amostras dos doentes apresentaram um 
maior conteúdo de lípidos saturados comparativamente aos não saturados, o 
que se traduz num potencial risco cerebral maior. Para além disso, foi observada 
a presença de ácidos carboxílicos, usualmente relacionados com hiperoxidação 
de lípidos, produção de carbonilos reativos e alterações estruturais e funcionais 
de proteínas. Por sua vez, a região espectral 1700-1400 cm-1 permitiu identificar 
diferenças na conformação de proteínas entre amostras controlo e de doentes, 
tendo estas últimas sido ainda relacionadas com a ocorrência de agregados 
proteicos. Por outro lado, a região 1200-900 cm-1 pôde ser relacionada com 
presença de danos celulares provocados por stress oxidativo nas amostras de 
doentes.  
Como importante nota a reter, a análise por FTIR pode ter o potencial para ser 
aplicada no futuro não apenas para diagnóstico de disfunção cognitiva, mas 
também para identificação do estádio da doença e realização de prognósticos, 
para além da avaliação do risco de desenvolvimento da doença em sujeitos 
controlo.  
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abstract 
 
Current clinical AD diagnosis criteria used to identify the disorder in patients who 
have already overt the advanced stage of dementia. This is too late for some 
kind of successful disease adjustment and consequently, early recognition of AD 
needs to be improved. Therefore, it is really needed different approaches for 
discovering new AD biomarkers, such as the application of metabolomics 
techniques (e.g. FTIR). The potential of FTIR in the clinical field has recently 
received particular attention, since it uses vibration frequencies of molecules 
present in the analysed sample to produce a metabolic fingerprint, which is then 
specific for each sample.  
This dissertation aims to identify biochemical alterations that might be related to 
dementia, being possible to distinguish between control and disease groups of 
plasma samples, through application of FTIR methodology at the 4000-600 cm-1 
spectral region. Using plasma samples makes the process being minimally 
invasive, with other relevant clinical advantages. Besides the collection of blood 
samples used in this project, the volunteers were also submitted to cognitive 
evaluation trough Mini Mental State Examination (MMSE) and Clinical Dementia 
Rating (CDR), with other relevant clinical information being also collected. All the 
analysed samples were matched by age and sex.  
For a better discrimination between control and disease samples, Principal 
Component Analysis (PCA) was applied to spectra data at specific regions, 
namely 3500-2700 cm-1, 1700-1400 cm-1, and 1200-900 cm-1. This allowed to 
identify the main pathological changes that occurred at the biochemical level 
during neurodegenerative disorder development. In the former spectral region, 
disease samples presented a higher content of saturated lipids in relation to the 
unsaturated ones, which translates in a high potential brain damage. Besides, it   
was also noted the presence of carboxylic acids that are usually related to lipid 
hyperoxidation, production of reactive carbonyls and proteins structural and 
functional alterations. In turn, the spectral region 1700-1400 cm-1 allowed to 
identify differences in protein conformation between control and disease 
samples, and these last ones were still related with occurrence of protein 
aggregates. In other hand, the 1200-900 cm-1 region could be associated to 
cellular damage provoked by oxidative stress in disease samples.  
As an important note to take, FTIR analysis could have the potential to be applied 
in future not only for cognitive impairment diagnosis but also for identification of 
disease stage and prognostic evaluation, besides assessment of disease 
developing risk for control subjects.     
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1. EPIDEMIOLOGY 
Alzheimer’s disease (AD) is the most common and most debilitating neurodegenerative disorder 
among older population, being usually developed after 65 years old with incidence of 67 per 1000 
in these ages. The risk of developing AD doubles with each 5 years of age, with more incidence 
among women. The estimated number in 2005 of AD patients was 24 million people worldwide, 
and leaning to grow at 81 million in 2040, with the major percentage of cases occurring in 
developing countries [1,2]. At an aging population as we have nowadays, diseases associated with 
old age are prone to become increasingly prevalent. Most of the increase in AD prevalence is 
projected to occur with people of the over-85 age group [3].  
Furthermore, AD substantially reduces life expectancy with the median survival time after diagnosis 
being around of 8,3 years for individuals diagnosed at 65 years old, which means an approximated 
67% reduction in media life span [4].  
AD is also the commonest dementia, accounting for over 65% of dementia in any age group [5]. 
Dementia is a major cause of disability in the older adult population. Although the actual prevalence 
of dementia is unknown, estimates range from 2,5% to 24,6% of those older than 65 years of age, 
with the number increasing with advanced age [6]. According to a WHO report, dementia could 
contributed 11,2% of years spent living with a disability in people over 60 years old – more than 
stroke, cardiovascular disease and cancer [7]. 
According to European studies until 2009, in Portugal there are 153 000 people suffering with 
dementia, from which 90 000 have AD. This means that about 1% of total Portuguese population 
suffer from this pathology [8].  
 
2. PATHOLOGICAL CARACTERIZATION  
AD has a gradual onset and a progressive course over several to 10 or more years, with death in a 
state of extreme cognitive decline [5]. This pathology is manifested by a progressive decline in 
several cognitive abilities, like memory, with functional and behavioural degeneration. It is thought 
that those clinical symptoms take place at 15 to 20 years after the beginning of pathological 
mechanisms behind of AD [2].  
The progressive loss of intellectual functions turns sufficient severe by interfering significantly with 
normal activities of daily living (ADL) and social relationships. It is important to differentiate AD 
from some benign age-related episodes of forgetfulness by its inevitable, progressive and 
irreversible declines in memory, time and space orientation, performance of routine tasks, 
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language and communication skills, abstract thinking, learning ability and, in a more advanced 
stage, personality changes and impairment of judgment [3]. Disturbance of gait, motor and 
occasionally sensory abnormalities and seizures are prone to occur in a later stage. AD cardinal 
clinical features are summarized in Table 1 and clinical stages are presented in Table 2 [5,6].  
 
Table 1| Main clinical features present in AD. 
Main Clinical Features of AD 
Progressive loss of ability to learn, retain and process new information (i.e. memory loss) 
Decline in language, with difficulty in naming and in understanding what is being said 
Apraxia – impaired ability to carry out skilled motor activities 
Agnosia – failure to recognize objects (e.g. clothing), places or people 
Progressive loss of executive function (organizing, planning and sequencing) 
Behavioural change (manifestation of agitation, aggression, wandering and persecutory delusions) 
Loss of insight, relative or complete 
Depression – though severe depression is unusual, perhaps because of loss in insight 
 
Table 2| Clinical staging of AD, characterized by progressive degenerative changes. Adapted from [6]. 
Stage 1 Initial stage that may last 2 to 4 years   
 Memory loss 
 Lack of spontaneity 
 Subtle personality changes 
 Disorientation to time and date 
Stage 2 Confusional stage  that may last several years 
 Impaired cognition and abstract thinking 
 Restlessness and agitation 
 Wandering, “sundown syndrome” 
 Inability to carry out ADL 
 Impaired judgment, lack of insight, inappropriate social behaviour 
 Repetitive behaviour  
 Voracious appetite 
Stage 3 Terminal stage that usually last for 1 to 2 years, with some exceptions 
 Emaciation, indifference to food 
 Inability to communicate 
 Urinary and fecal incontinence 
 Seizures 
 
2.1. Macroscopic characterization  
At a more gross level, there is an atrophy of neocortex and often of hippocampus and amygdala as 
well – all key sites involved in thinking and memory function. Atrophy is then most pronounced in 
the association cortices and is accompanied of widened sulci and narrowed gyri. Besides this, the 
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ventricular system is often enlarged, contributing to the atrophy (Figure 1). Also, melanin-
pigmented neurons are often much paler than normal [3,9].  
 
 
Figure 1|Schematic representation from a longitudinal section of preclinical AD brain (left) and brain in AD 
severe stage (right), with emphasis on the progressive character of ventricles enlargement and cortex 
shrinkage. Adapted from [10]. 
 
Despite of classical relevance of atrophy in AD morphological characterization, this is more 
prominent in younger patients where disparity with control cases is bigger. Therefore, while 
atrophy is of cursory diagnostic value in younger individuals, in majority of cases this is not used in 
the routine pathologic diagnosis of AD. Nonetheless, AD brains do tend to be about 8% - 15% 
smaller than age-matched controls [9]. 
 
2.2. Microscopic characterization 
At a microscopic level, the most common and distinctive hallmark lesions present within the AD 
brain are amyloid or senile plaques (SP), which consists on intracellular aggregates of amyloid-β 
(Aβ) peptides, and neurofibrillary tangles (NFT), that results from the accumulation of 
hyperphosphorylated tau protein. These AD pathological hallmarks affect firstly the medial 
temporal and parietal lobe, and part of the frontal cortex of the brain, resulting in the symptomatic 
pattern already mentioned above [1,9]. Other closely related lesions include neuropil threads and 
dystrophic neurites (terminal neuritic swellings) that occur within neuritic plaques, in the case of 
neuropil threads specifically in corona of these plaques. Neuropil threads represent swollen 
dendrites with thread like accumulations of phosphorylated tau (p-tau) within grey and white 
matter neuropil, occurring in the same topography as NFT and mainly present at earlier stages of 
disease. Neuronal and dendritic loss, cerebral amyloid angiopathy, Hirano bodies and 
granulovacuolar degeneration are also typical of the AD brain [9,11].  
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2.2.1. Senile Plaques (SP) 
Senile, or neural, plaques are spherical extracellular lesions with 10 to 200 μm of diameter (Figure 
2), which can be found in both intellectually normal individuals and dementia patients. They are 
distributed predominantly within the cortical and various neocortical areas. Two major subtypes of 
these plaques are recognized: neuritic and diffuse [3,9].  
 
 
Figure 2|Several microscopic presentations of Aβ aggregation with emphasis for senile plaques. Left: 
presence of β-amyloidosis in the frontal lobe, showing a diffuse plaque (D), a neuritic plaque with its central 
core and corona well demarcated (C), and cerebral amyloid angiopathy (A); β-amyloid (10D5) 
immunohistochemistry. Upper right corner: senile plaques with neurites fragmentation within neuropil grey 
matter; Bielschowsky silver stain. Down right corner: diffuse plaques in a cerebral cortex sample, Aβ (4G8) 
immunohistochemistry. Adapted from [9,12,13].  
 
The typical neuritic, classical, or compact plaques are strongly associated with AD and consists in 
spherical extracellular structures of 10 to 50 μm in diameter, with thickened neuronal processes (or 
neurites) surrounding an amyloid central fibrillar core that is made of 6 to 10 nm Aβ proteins 
filaments arranged as bundles radiating from the centre. Furthermore, these neuritic plaques 
contain dense bodies thought to be the remains of lysosomes, mitochondria and paired helical 
filaments (PHF, in plaques periphery). Aβ protein, amyloid precursor protein (APP), tau and 
neurofilament proteins, are all found in the peripheral region of neuritic plaques [3,9,14]. The 
invariable presence of activated microglia in these plaques comprises the basis for the hypothesis 
that AD is a disease of excessive inflammation within the brain [9].  
In other hand, diffuse plaques lack abnormal neurites, appear more amorphous and contain little if 
any fibrillar amyloid, in other words, they do contain amyloid but in a diffuse form. They tend to be 
more heterogeneous in size with a frequency that decreases with increasing size such that most 
diffuse deposits are less than 20 μm in diameter. Diffuse plaques are the earliest cerebral lesions in 
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AD and it has been proposed that they may progress to neuritic plaques, depending on several 
factors (e.g. longevity). However, even in severe and longstanding AD cases, diffuse plaques 
account for the majority of Aβ protein-immunoreactive material. Furthermore, this does not 
necessarily imply an evolution from one type to another and might represent diverse mechanisms 
of SP formation that follows different morphogenic kinetics [3,9].  
Giving the progressive degeneration process, SP are followed by neuron apoptosis with a marked 
reduction in choline acetyltransferase, acetylcholine, noradrenaline and serotonin, as it seen ahead 
(2.2.5 and 6.2) [5].  
2.2.2. Neurofibrillary Tangles (NFT) 
NFTs are intracellular clusters found within neuronal cell bodies or dendrites and composed mostly 
of PHFs, which consists in 10 nm protein filaments helically twisted about each other in pairs. These 
PHFs proteins are abnormally phosphorylated forms of tau protein, which is usually a microtubule 
associated protein (MAP), and are complexed with ubiquitin that is a protein normally used by cell 
to label proteins destined for degradation. Tangle-bearing neurons also contain structures known 
as neuropil threads, which are composed of either paired helical or nonhelical filaments in their 
axons or dendrites or both (Figure 3) [3,5,9,15].  
 
 
Figure 3| Neurofibrillary tangle microscopic presentation after immunohistochemical stain for tau protein 
(AT8). Special reference to the neuropil threads in the background (left), and flame-shaped NFTs and its 
globose form in the inset at 200x magnification (right). Adapted from [9,11] 
 
Some clinicopathologic findings indicate that p-tau typically occupies viable cells and accumulates 
with age, often in significant amounts. In fact, NFTs are also found in non-demented adults, its 
deposition begins around to 30 years and increases with age. Recently, it has been suggested that 
tau lesions may be a manifestation of protection or cellular adaptation with age [9,16]. 
Nevertheless, NFT number in AD affected brain is approximately six times greater than NFT number 
present in most severely affected intellectually capable individuals [3].  
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NFTs are located primarily in large pyramidal neurons of Ammon’s horn (hippocampus) and in the 
cerebral neocortex, although it is also encountered in deep structures, including midbrain, pontine 
tegmentum, basal nucleus of Meynert and hypothalamus [9]. In intellectually normal old 
individuals, NFTs may be found at the anterior temporal lobe, but rarely appear in other brain 
regions such as the neocortex [3].  
Despite being hallmark lesions for AD, NFT can also be present in other neurological disorders, 
which could difficult making of differentiate diagnosis [3].  
2.2.3. Cerebral Amyloid Angiopathy (CAA) 
CAA consists in the Aβ deposition within the walls of leptomeningeal, cerebral cortical and 
cerebellar blood vessels, with tendency to formation of highly insoluble fibrils. It appears in 90% of 
AD patients, nevertheless there is no evidence suggesting that progression of cognitive decline 
differs between those subjects with and without CAA. Further, the severity of this deposition differs 
widely, and it is sometimes found in aged healthy brains [3,4,9]. Like SP and NFT, CAA are seen 
especially within hippocampus and frontal, temporal and parietal cortices [5].  
This condition may lead to vascular rupture and multiple lobar haemorrhages, with APOE ε2 allele, 
considered a protective factor for AD development, being associated with an increased risk of CAA-
related haemorrhage [4,9].  
2.2.4. Other Lesions 
Hirano bodies are intraneuronal rod-like inclusions of 15 to 30 μm in length, which are located 
primarily in hippocampus and whose frequency generally increases with normal aging and in AD, 
besides their usually presence in Pick disease and alcoholism. It is thought that a breakdown of the 
microfilament system is involved in their formation. Although their accumulation is an age-
associated phenomenon, Hirano bodies role in AD pathogenesis is doubtful [9]. 
Granulovacuolar degeneration corresponds to granules, within a membrane-limited vacuole about 
3 to 5 μm in diameter, which are frequently located in cytoplasm of pyramidal neurons of the 
hippocampal formation, and also found in smaller numbers at neocortex of AD brains. This is not 
specific for AD and it is also present in healthy aged individuals, albeit at lower frequency, as well 
as in other neurologic conditions [9]. 
2.2.5. Neuronal Loss 
Pyramidal cells, the most abundant cortical neurons, appear to be the main substrate of 
neurodegeneration. This is because pyramidal neurons use EAAs (namely glutamate and aspartate) 
as neurotransmitters and receive prominent excitatory inputs, and it is thought that changes in EAA 
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neurotransmission are the major cause of AD cognitive impairments, particularly memory function. 
Besides, these neurons are responsible for connecting entorhinal cortex with hippocampus 
(perforant pathway), whose neurodegeneration is a very early change in AD. In the other hand, 
evidences suggest that loss of noradrenergic and serotonergic neurons in AD contributes to 
behavioural and psychological symptoms of dementia, including depression, psychosis, anxiety and 
aberrant motor activity [15].  
Associating the progression of neuron loss with SP and NFT distribution allows the establishment 
of three pathological stages, as AD neurodegeneration spread (Table 3). Perforant pathway begins 
to be lost in the transentorhinal stage and progresses through the next stages, limbic and 
isocortical. Loss of the ascending cholinergic, serotonergic and noradrenergic neurons (from nbM, 
RN and LC, respectively) begins at the limbic stage and progresses further in the isocortical stage, 
when GABAergic interneurons start to degenerate [15].  
 
Table 3|Stages of AD progression, according to SP and NFT anatomical distribution and advancement of 
neuronal loss. Arrow direction relates to different disease stages order, affecting diverse SNC regions. 
Adapted from [15].   
   
Transentorhinal Stage Limbic Stage Isocortical Stage 
 
 
 
 
 
 
 
 
 
Besides neurotransmitters depletion, the normally high levels of neurotrophin receptors in 
cholinergic neurons of the basal forebrain are severely reduced in late-stage AD. This contribute for 
progression of neuron loss 
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synaptic failure in AD, since neurotrophins promote proliferation, differentiation and survival of 
neurons and glia, besides their role mediating learning, memory and behaviour [17].  
 
3. TYPES OF ALZHEIMER’S DISEASE 
According to age of onset, AD can be divided into early (<60-65 years) and late (>60-65 years) onset 
forms. In other hand, according to family history, AD may be classified as autosomal dominant, 
familial or sporadic, with the latter mainly presenting a later onset of disease [4].  
 
3.1. Familial AD 
Autosomal dominant familial AD, being termed early-onset AD (EOAD) or familial AD (FAD), 
accounts for less than 5% of all AD cases and its onset occurs predominantly before 65 years old. 
Genetic studies have shown linkage between familial (presenile) AD and loci on chromosome 1 
(presenilin, PS1 gene), chromosome 14 (presenilin, PS2 gene) and chromosome 21 (amyloid β-
protein precursor, APP gene). This last one can explain the increased incidence of AD among Down’s 
syndrome patients, whose have an extra copy of APP gene since they have one more 21 
chromosome than other people (gene dosage effect) [5,14,15]. In fact, all individuals afflicted with 
Down’s syndrome develop symptoms indistinguishable from those of AD by the age 50, and they 
show diffuse plaques as early as the age 12 [3]. Nevertheless, the finding that age of onset of 
cognitive decline differs substantially between those with isolated APP duplication and those with 
chromosome 21 trisomy suggests that Down’s syndrome is not a faithful model of EOAD, let alone 
LOAD [16].  
Duplication of APP gene gives rise to Aβ deposition in brain neuropil and/or in cerebral blood 
vessels, with clinical pictures of AD or recurrent brain haemorrhages. These findings are reminiscent 
of Down’s syndrome, although brain haemorrhages are rarely observed [14]. 
Between the aforesaid mutations, the one in PSEN1 is the most common cause of EOAD, and in the 
opposite frequency position is mutations in PSEN2, with both of genes encoding a component of 
the proteolytic enzyme γ-secretase. All mutations known to cause EOAD are associated with 
abnormal APP proteolytic processing that leads to increased production of Aβ42, the most abundant 
APP-derived component of SP [9,15]. Indeed, presenilin gene mutations increase the ratio of Aβ42 
to Aβ40, which appears to result from a change in function that manifests itself in reduced γ-
secretase activity [14].  
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3.2. Sporadic AD 
Late-onset AD (LOAD), or sporadic AD, represents the great majority of AD cases (>95%) and is 
probably a heterogeneous disorder. Evidence suggests a link between AD and atherosclerosis, 
inflammation and cholesterol. LOAD is not associated with deterministic gene mutations, it is 
instead genetically influenced. It has been found relation between AD and a gene locus on 
chromosome 19q, with special relevance for gene encoding apolipoprotein E (APOE), which has 
three alleles (ε2, ε3, ε4). APOE is a protein, in CNS secreted mainly by astrocytes and microglia, with 
physiological function that supports transporting lipids among CNS cells to keep lipid homeostasis, 
repairing injured neurons, maintaining synaptic connections and scavenging toxins. The APOE ε4 
allele is the major genetic risk factor in AD, increasing the risk for developing LOAD – individuals 
with two of these alleles have more than seven times increased risk of suffering from AD compared 
with those who have APOE ε3 alleles. Besides, it is possible that Aβ accumulation is more extensive 
in those with this allele than those lacking it. In the other hand, it is thought that the under-
represented ε2 allele is protective against AD, and ε3 allele, the most common APOE allele found 
in general population, plays a neutral role in disease. Therefore, although an APOE ε4 allele is not 
deterministic for AD, having this allele tends to move up age of onset in those perhaps destined to 
develop AD anyway [5–7,15,16,18].  
An increased risk for AD is also associated with genes linked to cytokines, chemokines and nitric 
oxide synthases. Besides, APOE ε4 allele is associated with other aspects that may contribute to AD 
as low glucose usage, mitochondrial abnormalities and cytoskeletal dysfunction [7,14].   
 
4. PATHOGENESIS 
The complex molecular mechanisms of AD are supported by Aβ, tau and cholinergic theories, 
besides its genetic basis that accounts for the difference in symptomatology processes activation 
among human population [19]. Currently available evidence strongly supports the position that 
initiating event in AD is related to abnormal processing of Aβ peptide, that leads to excess 
production or reduced clearance of Aβ in the cortex and ultimately to Aβ plaques formation, leading 
to all AD associated clinical, histopathological, molecular and biochemical manifestations. This is 
known as amyloid cascade hypothesis and occurs while individuals are still cognitively normal 
[16,20].  
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4.1. Aβ cascade hypothesis 
4.1.1. APP processing and Aβ formation, clearance and transport mechanisms 
Aβ peptide is produced by proteolytic processing of the amyloid precursor protein (APP), an integral 
membrane glycoprotein, which is firstly cleaved by either α or β-secretase producing soluble sAPPα 
or sAPPβ fragments and membrane-bound C-terminal fragments (CTFα or CTFβ), respectively. 
When CTFα is cleaved by γ-secretase there is liberation of p3 peptide, while when γ-secretase 
cleaves CTFβ the product is Aβ (as it is cleaved at two different sites, it is generated two Aβ forms 
– Aβ40 and Aβ42) and APP intracellular C-terminal domain (AICD), as it shows Figure 4. Comparing 
the 40 or 42 amino acids long Aβ species, the more amyloidogenic Aβ42 form is deposited first 
[1,14,18]. The availability of APP to α-secretase (nonamyloidogenic pathway) or β-secretase 
(amyloidogenic pathway) determines how much of the pathogenic Aβ peptide will be produced. 
Since these two secretases/pathways are likely to be spatially separated within the cell (Figure 4), 
it is possible that changes in APP trafficking, caused by lipid alterations, may be the primary cause 
of AD process [1]. Indeed, a possible defect in cholesterol metabolism ties together the APOE 
genetic risk, amyloid production and aggregation, and vasculopathy of AD. Cholesterol is an 
essential component of neuron membrane being concentrated in lipid rafts (Figure 4), which are 
platforms for the assembly of β and γ-secretases and processing of APP into Aβ. Furthermore, Aβ 
generation and aggregation are promoted and its clearance from the brains is reduced when an 
overabundance of esterified cholesterol decreases membrane lipid turnover [17].  
 
 
Figure 4| APP processing via nonamyloidogenic and amyloidogenic pathway. The β-site amyloid precursor 
protein-cleaving enzyme 1 (BACE-1) is the main β-secretase cleaving APP. It is shown a lipid raft that is a 
tightly packed membrane micro-environment enriched in sphingomyelin, cholesterol and 
glycophosphatidylinositol (GPI) – all of them are anchored proteins. Adapted from [17]. 
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After being produced, Aβ is secreted outside the cell and binds to various isoforms of APOE, which 
will allow Aβ to undergo in different metabolism pathways (e.g. clearance via BBB, degradation by 
insulin-degrading enzyme (IDE) or neprilysin (NEP), deposition or trafficking into the cell). Affinity 
of APOE4 to Aβ is lower than that of APOE2 or APOE3. Thus, while this two later isoforms help Aβ 
to be cleared by transport or degradation, APOE4 mainly induce Aβ aggregation implicating it to be 
a high risk factor for AD (as aforesaid). Besides, contrarily to the other isoforms, APOE4 is more 
sensitive to stress or injury, which causes neuron-specific proteolysis with formation of a bioactive 
toxic C-terminal fragment that could induce tau phosphorylation. There is a feedback mechanism 
to keep Aβ homeostasis: when Aβ is produced, AICD is released and translocated into the nucleus 
initiating neprilysin transcription, which will degrade Aβ and hereby reduces Aβ to a proper level. If 
this Aβ levels balance is disrupted, Aβ will be oligomerized and lead to formation of fibrillar Aβ 
protein (fAβ), which can inhibit proteolytic activity of NEP and IDE, leading to the generation of a 
positive feedback that accelerates amyloid deposition. Both expression and activity of NEP are 
significantly decreased in AD brain, with NEP levels declining in an age-dependent manner and 
inversely correlating with insoluble Aβ levels in temporal and frontal cortex. IDE mRNA and protein 
levels are markedly decreased in hippocampus of AD patients carriers of APOE ε4 allele, besides IDE 
levels and activity presented significantly reduced in MCI subjects and appear to continuously 
decrease during MCI to AD progression [17,18].  
It was further proposed that, via regulation of gene transcription, AICD facilitated creation of a 
feedback loop through which APP protein status could modulate transcriptional activation of APP 
gene itself [16]. APP shows having physiological functions especially in regulation of synaptic 
function and neuronal activity. Besides, APP processing regulates cholesterol metabolism and 
present a normal negative feedback function in modulating Aβ levels, to maintain proper neuronal 
activity [18]. 
 Aβ transport across the blood-brain barrier (BBB) occurs through LDL receptor-related protein 1 
(LRP1), and once in vascular system Aβ is cleared via transport into the blood or via the perivascular 
fluid drainage pathway. However, in AD brain the clearance via LRP1 is disturbed, resulting in the 
accumulation and aggregation of Aβ peptide [14,21]. Furthermore, during the onset of disease, the 
transfer of autophagic vesicles to the lysosomes is impeded, thus promoting Aβ accumulation, and 
secondly microglia cells cannot destroy efficiently abundant Aβ monomers through phagocytosis 
[19].  
Aβ is a normal secreted product, which suggests that it has a physiological function, although it is 
still unknown. APP mutations increase Aβ production or lead to an increased proportion of Aβ42. 
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Missense mutations in Aβ lead to vascular deposits, parenchymal plaques or both, since mutations 
in Aβ have little effect on APP processing but, in other hand, they increase the Aβ propensity to 
form fibrils [14]. 
4.1.2. Senile plaques and the triggering of AD neurodegeneration process 
In the amyloid cascade hypothesis, Aβ deposits are toxic and cause synaptic dysfunction and 
neuronal cell death (Figure 5). Aβ oligomers are able to bind specifically to excitatory pyramidal 
neurons and affect their synaptic structure, composition and density, as well as membrane 
expression of NMDA receptors. Furthermore, Aβ plays an important role in activity-dependent 
presynaptic vesicle release [7,18]. Besides, it proposes that changes in tau and consequent NFT 
formation are triggered by toxic concentrations of Aβ, although the linking between Aβ and tau are 
not yet clearly understood, as well as NFT contribution for AD neurodegeneration [7,22].  
Primary role of tau is to stabilize neuronal cytoskeleton, by interacting with microtubules. 
Decreased affinity and dissociation of tau from microtubules, probably by phosphorylation (the 
most common tau post-translational modification), results in microtubule destabilization with 
cytoskeleton damage. This leads to disruption of tau-dependent cellular functions including axonal 
growth, vesicle and organelle transport, as well as nervous signal propagation along microtubule 
nerve network. Newly soluble tau proteins are targeted by post-translational modification that 
directly or indirectly alter tau conformation, promoting tau dimerization. These tau dimers form 
tau oligomers, which continue aggregating and constitute subunits of filaments called protomers. 
Two protomers around each other formed PHFs, whose assembly make NFTs [17,22].  
 
 
Figure 5| Neurodegeneration main steps according to the cascade amyloid hypothesis. 
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Tau phosphorylation level is mainly determined by a balance between kinases and phosphatases 
activity, which when disrupted contributes to tau abnormal phosphorylation observed in AD, 
especially overactivation of GSK3β and inhibition of PP2A (protein phosphatase-2A). In fact, PP2A 
activity has been shown to be decreased by 50% in AD brains, and alterations in expression and/or 
activity of some tau kinases (GSK3β, CDK5, DYRK1A, p38 and CK1) have been already reported in 
AD. Nonetheless, tau phosphorylation is not constantly accompanied by its aggregation, so it is 
thought that additional post-translational modification are required for development of NFTs, 
including cleavage, glycation and nitration. Regardless of this, tau by itself has been reported to 
mediate Aβ-induced neurotoxicity. In other hand, Aβ overproduction has been shown to induce 
caspase-3-dependent cleavage of tau, to activate GSK3β and to inhibit UPS activity, which promotes 
tau aggregation [22].  
Aβ deposition is also associated with local inflammatory and immunologic alterations, with 
microglia around plaques maintaining their stability. Although Aβ may have direct neurotoxicity, at 
least some of its toxicity might be an indirect consequence of an Aβ protofibril-induced microglia 
activation and astrocyte recruitment. This inflammatory response may represent an attempt to 
clear Aβ deposition. However, it is also associated with release of cytokines, nitric oxide and other 
radical species, and complement factors that can injure neurons and promote ongoing 
inflammation. Indeed, levels of multiple cytokines and chemokines are elevated in AD brains, and 
certain pro-inflammatory gene polymorphisms have been related with AD [16,18]. 
Prudently named prionoids, Aβ aggregates have not yet been shown to be infectious (i.e. 
contagious) under natural conditions. However, demonstration of inter-individual transmissibility 
would warrant upgrading the status of such agents to bona fide prions [23]. In other hand, once 
filamentous tau has formed, it can be transmitted to other brain regions [7]. 
 
4.2. The role of aging in AD pathogenesis 
The strong association of AD with aging suggests two possibilities: first, that there might be an 
intimate coupling of AD with an underlying process of aging, possibly involving the age-related 
increase of damage processes and decreased efficiency of repair mechanisms; second, that the 
disease might be dependent on some slow, time-dependent processes that take a long time to 
reach a critical threshold. In this second possibility, AD might not fit the strict definition of an age-
related change. Furthermore, if AD actually be a similar sort of time-dependent process, then this 
would imply that individuals fated to develop AD should have brain characteristic abnormalities at 
an early, presymptomatic age [3].  
 
  16  
 
Regardless of whether one is genetically predisposed or not, aging is an essential factor in AD, 
suggesting that an age-related process is involved in its development. It has been emphasized a 
discernible difference, clinical and pathologic, between AD and senile dementia (a manifestation of 
advanced age per se) [9].  
 
4.3. Oxidative Stress 
Since the brain is characterized by high energy consumption, mitochondria become crucial as an 
energy source, besides its role in controlling a wide range of cellular processes such as aging. 
Unfortunately, production of free radicals [hydrogen peroxide (H202), hydroxyl (·OH) and 
superoxide (O2-·)], in which the brain is especially vulnerable, is an undesirable consequence. The 
reactive oxygen species (ROS), generated as a by-product of ATP synthesis in mitochondria, have 
many targets such as lipids, proteins, RNA, DNA and mitochondrial DNA (mtDNA). Oxidative stress 
is increased during aging, similar to the increased susceptibility seen during AD. It has been strongly 
linked to neuronal dysfunction and death, and it has also been suggested as a central mediator of 
toxicity. Under degenerative conditions, cells capacity to maintain redox balance decreases 
resulting in mitochondrial and metabolic dysfunction, deregulation of metal homeostasis and 
changes in cell cycle [21,24].  
Moreover, it is thought that increase in free radical formation and failure of antioxidant defences 
may contribute to neurodegeneration. In fact, superoxide dismutase (SOD), the free radical defence 
enzyme, is reduced by some 25% in AD frontal cortex and hippocampus [5]. Besides, evidence 
supports the close dependence between mitochondria and brain activity, so it is not surprising that 
significant reduction of intact mitochondria and microtubules has been found in AD. Furthermore, 
changes in mitochondrial enzymes, structure, localization and mobility are all involved in AD [24].  
It is already known that oxidative stress, protein deposition and synaptic failure are crucially 
involved in AD neurodegeneration process. However, the order in which they appear during 
pathological progression and the identity of the mechanism that links them remains under 
extensive study. Evidence supports that mitochondrial and metallic abnormalities are direct 
precursors of oxidative stress during the early stages of disease [24].  
NFTs are associated with impaired axonal transport of mitochondria between cell nucleus and 
synaptic terminal, which leads to severe energy dysfunction and imbalance in ROS and reactive 
nitrogen species (RNS) production, resulting in the AD typical synaptic failure. In other hand, data 
suggests that oxidative stress in synaptic terminals are able to affect downstream targets (e.g. 
GSK3β) that have direct repercussion in tau phosphorylation levels, whose balance appear to 
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determine whether tau contributes to synaptic formation or synaptic failure through NFTs. Thus, 
altered tau can create a pathological feedback loop with mitochondria that leads to synaptic failure 
[24].  
According to one of the several hypotheses addressing Aβ toxicity, amyloid oligomers access 
intracellular organelles such as mitochondria and compromise their function [16]. Upon entering 
the mitochondria, Aβ binds to molecules that might play a cytoprotective role (e.g. ABAD, β-amyloid 
binding alcohol dehydrogenase, that detoxifies aldehydes as 4-HNE), inhibiting theirs action and 
leading to mitochondrial dysfunction and ROS production. Aβ induced mitotoxicity is still not clear, 
but may include several mechanisms such as increasing membrane permeability (interaction with 
MPTP), reducing of respiratory function and inclusive oxidative phosphorylation, enhancing 
vulnerability to other toxics, distressing calcium homeostasis, disturbing mitochondrial dynamics 
and distribution, inducing mitochondrial DNA/RNA mutations and even apoptosis, besides 
increasing ROS production. Furthermore, Aβ seems to decrease cytochrome c oxidase activity, 
leading to impairment of electron transport, ATP production (and Aβ-induced ATP synthase 
affection induces even more ATP depletion), oxygen consumption, and once again of mitochondrial 
membrane potential. Aβ tends also to increase mitochondrial fission, leading to its fragmentation 
and contributing to cell death. Oxidative stress resulting from excessive ROS production may be 
implicated in mitochondrial DNA and RNA point mutations in AD, nevertheless further studies are 
still required on this [17,21].  
Lastly, Aβ and tau may act in synergy on oxidative stress and mitotoxicity, since both shown to 
affect respiratory capacity by acting on the cytochrome complexes [21]. In other hand, oxidative 
stress and mitochondrial damage, as cellular changes associated with aging per se, are able to 
contribute for amyloidosis development [16].  
 
4.4. Other risk factors for AD development 
Besides age and genetic factors, other issues associated with dementia include sex, comorbidity, 
environmental factors and lifestyle. Sex is an important risk factor for AD among elderly population, 
with several studies showing a higher prevalence of disease among women [25]. It could be 
associated with decrease in estrogen hormone in postmenopausal women that may have a more 
effective neuroprotective role than testosterone against AD development [19].  
Several studies have observed that physical activity has a positive effect on cognitive function 
among older population, with significant reductions in cognitive decline. This protective effect of 
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physical training might results of reduced vascular risk and obesity, lower levels of inflammatory 
markers, enhanced fitness, neuronal health and positive behaviour [25].  
Overweight and obesity are risk factors of AD, since weight loss can reflect underlying diseases and 
obesity can be related to subsequent vascular diseases. On average, around half of individuals with 
vascular cognitive impairment might develop dementia within 5 years after a stroke. As a whole, 
infections, vascular factors and related diseases, head injury and psychological conditions can share 
a common inflammatory pathway that contributes to the etiology of dementia. Furthermore, 
hyperinsulinemia and DM II (type 2 diabetes) is strongly associated with insulin resistance (inclusive 
central resistance), which is related to Aβ formation and presence of inflammatory agents in brain, 
with subsequent increased AD risk. Besides, resistance to insulin signalling renders neurons energy-
deficient and vulnerable to oxidizing or other metabolic insults, and impairs synaptic plasticity. 
Hyperinsulinemia also damage directly the hippocampal structures, up-regulate GSK3β and reduce 
IDE levels in AD brain [17,25].  
Some macronutrients, such as glucose, protein (tryptophan and tyrosine) and unsaturated fatty 
acids, have been linked to age-related changes in cognitive function among AD and VaD (vascular 
dementia) patients. Dementia can be exacerbated via oxidative stress as a result of higher energy 
and lower antioxidant intake. It is known that excessive intake of n-6 polyunsaturated fatty acids 
(PUFAs) or deficiency of n-3 PUFAs may lead to chronic inflammation, platelet aggregation or 
microvascular endothelial dysfunction [25].  
An important early predictor of AD may be lower levels of mental activity at young ages. 
Furthermore, it has been already stated that high levels of education, verbal ability and/or 
continuing mental activity allows at least some individuals to function at normal behavioural and 
cognitive levels, despite the ravages of AD. This may be explained with the multiple additional 
neural pathways, by which information can get in and out, and that results from mental activity 
stimulation of complex neural circuits [3].  
4.4.1. Genetic risk factors 
A recent genome-wide association study of AD identified two loci that were not previously disease-
associated: CLU (encoding clusterin) and PICALM (phosphatidylinositol-binding clathrin assembly 
protein), also known as CALM (clathrin assembly lymphoid-myeloid leukemia gene). Clusterin 
(apolipoprotein J), in a similar manner to APOE, may regulate both toxicity and solubility of  Aβ. 
Furthermore, APOE and clusterin have been shown to cooperate in suppressing Aβ deposition, and 
they might modify Aβ clearance at the BBB, which could suggest a role for clusterin in the 
amyloidogenic pathway. Clusterin levels are increased in proportion to APOE ε4 allele dose levels, 
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suggesting an induction of clusterin in individuals with low APOE levels. In other hand, genetically 
directed changes in PICALM function may lead to synaptic dysfunction, possibly through synaptic 
vesicle cycling, thereby increasing risk for AD. Alternatively, PICALM could influence AD risk through 
APP processing via endocytic pathways, altering Aβ levels [9,20].   
As aforesaid, inflammation is an important process in AD pathogenesis, with recent studies showing 
that polymorphisms of one of the inflammatory genes alone or in combination have comparable 
effects on AD risk to those for the APOE ε4 allele. Homozygous carriers of high-risk alleles, such as 
IL-1-α-889 and IL-1β+3953, or the combination of APOE ε4 allele and high-risk allele of TNF-α, could 
predict people at high AD risk [25].  
Considered as a genetic risk factor, sortilin-related receptor 1 (SORL1), a γ-secretase substrate, is 
known to regulate APP trafficking and processing with enhancement of Aβ accumulation in both 
EOAD and LOAD, since SORL1 reduces interaction between APP and β-secretase. Furthermore, 
interaction between APOE4 and SORL1 single nucleotide polymorphisms on Aβ42 CSF indicate the 
role that SORL1 genetic variants can have in regulating amyloidogenic pathway. An overexpression 
of SORL1 results in reduced Aβ production, which occurs with binding of SORL1 to APP. Thus, SORL1 
concentrations are reduced in AD patients [7,19].   
 
5. DIAGNOSIS  
Nowadays, AD is fully diagnosed only by post-mortem analysis of the brain, and although the 
current clinical diagnosis criteria (DMS-IV, ICD-10 and NINCDS-ADRDA) presents an accuracy of 
about 80%, it used to identify AD in patients who have already overt dementia correspond to 
neuropathological advanced disease. This is too late for some kind of successful disease adjustment 
and consequently, early recognition of AD needs to be improved, especially since it was estimated 
that interventions capable of delayed clinical onset of dementia by one year would decrease disease 
prevalence in 2050 by 9 million cases [26,27].  
Until recently, AD clinical diagnosis criteria established in 1984 by NINCDS-ADRDA have been used 
in common clinical practice and research, without modification. These criteria relies mainly on 
clinical history, physical examination, laboratory tests, neuroimaging and neuropsychological 
evaluation [20,26]. However, there is now a broad consensus that these criteria should be revised 
to incorporate new scientific knowledge that has been emerged in the last 30 years. The new 
proposed criteria differs manly from the 1984 criteria by incorporation of biomarkers of the 
underlying disease state and formalization of AD different stages [20,28].  
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It is made a distinction between syndromic labels that denote different qualitative and quantitative 
clinical expressions of disease (preclinical phase, pre-dementia or MCI phase, dementia phase), and 
pathophysiological process that underlies the syndrome acting as a neurodegenerative continuum. 
The core clinical criteria regarding AD dementia and MCI due to dementia are intended to guide 
diagnosis in the clinical setting, while the new recommendations for preclinical AD phase are 
intended only for research purposes, do not having any clinical utility at this time. It is important to 
note that in the preclinical phase, biomarkers are used to establish the presence of AD 
pathophysiology process in research subjects with no or very subtle overt symptoms. While, in both 
MCI and AD dementia criteria, clinical diagnoses are paramount and biomarkers are 
complimentary. Furthermore, development of biomarker standardization is needed before 
widespread adoption of these renewed guidelines at any AD stage [20]. 
MCI due to AD, symptomatic pre-dementia phase of the disease, corresponds to a degree of 
cognitive impairment that is not normal for age and that progress gradually to a state of dementia, 
when there is significant interference in the ability to function at work or in ADL [28,29]. The core 
clinical criteria for MCI comprises the following issues: concern regarding a change in cognition; 
impairment in one or more cognitive domains including memory (impairment in episodic memory 
is common in MCI patients that progress to AD dementia), executive function, language and 
visuospatial skills; independence preservation in functional abilities including ADL; without 
evidence of significant social or occupational impairment. Besides, cognitive tests scores of MCI 
patients usually present 1-1,5 standard deviations below the mean for their age and education 
matched peers [29]. 
The diagnosis of dementia state in AD is intended to encompass a severity spectrum, ranging from 
the mildest to the most severe stages of dementia. Thus, proposed AD dementia classification are 
the following: probable AD dementia; possible AD dementia (atypical clinical presentation); 
probable or possible AD dementia with evidence of AD pathophysiological process (currently 
intended terminology only for research purposes) [28]. 
Other two recent publications by an international working group also emphasize the importance of 
AD diagnostic criteria revision, being also proposed a panel of reviewed criteria and AD lexicon, 
with insight in potential diagnostic role of biomarkers and differentiation between AD stages, 
including separating various prodromal/preclinical AD phases [30,31]. Nonetheless, these proposed 
criteria have not been validated and there is discussion on which neurocognitive tests should be 
used for characterization and quantification of cognitive deficits, as well as on which are the best 
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auxiliary biomarkers, definition of their pathological threshold and their clinical value in each 
patient [11].  
 
5.1. Genetic Tests  
The amount of AD risk that is attributable to genetics is estimated to be around 70% [7]. The 
advance of high-throughput genotyping techniques (e.g. microarrays) and statistical tools have 
allowed extensive access to association between genetic factors and risk of dementia [25].  
According to the American College of Medical Genetics (ACMG) and the National Society of Genetic 
Counsellors (NSGC), tests for EOAD associated genes (currently APP, PSEN1 and PSEN2) are useful 
for: 
 Symptomatic patients with EOAD; 
 Individuals with a family history of dementia with one or more cases of EOAD; 
 Individuals with a relative affected by a known mutation of abovementioned genes [4]. 
Thus, for these rare autosomal dominant mutations, genetic tests are available in selected 
circumstances. In the other hand, although APOE genotyping is commercially available, this is not 
recommended at present due to limited clinical utility and poor predictive value. Otherwise, it 
cannot be used as a surrogate or substitute for clinical diagnosis [4,16].  
 
5.2. Neuroimaging in AD diagnosis 
To complement clinical observations and improve clinical trials research, it could be used several 
molecular imaging techniques such as structural resonance imaging (MRI), functional MRI (fMRI), 
proton-magnetic resonance spectroscopy (1H-MRS) and positron emission tomography (PET) [27].    
In MRI structural studies, it is correlated MRI-based volume with neuron numbers in specific brain 
regions [27]. In AD, main structural changes are global cerebral volumetric reduction, increased 
ventricular volumes and regional atrophy of medial temporal lobe. Novel quantitative techniques 
for structural imaging analysis, such as volumetric imaging, three-dimensional mapping of the 
hippocampus and cortical thickness measurement, are being investigated as promising markers for 
AD. These techniques and potential functional imaging with PET might address the metabolic 
changes that presumably antedate structural damage [7,32].  
The blood oxygen-dependent level (BOLD) fMRI signal is a measure of the input and processing of 
neuronal information within a brain region, which might be associated to a hypoperfusion global 
pattern in AD.  Further, studies of memory in AD patients using fMRI discovered a pattern of altered 
activation consistent with structural MRI results [27,32].  
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1H-MRS provides quantitative analysis of the biochemical composition of brain tissue, being its best 
established marker the amino acid N-acetyl aspartate (NAA), which reflects the functional status of 
neuronal mitochondria. Indeed, a reduction in NAA levels independent of brain atrophy is a 
consistent finding in AD. Other metabolites are detectable with 1H-MRS, but their potential as 
biomarkers candidates requires refined investigations [27]. 
PET with fluorodeoxyglucose (FDG), that represents neuronal glucose consumption as the main 
determinant of neuronal metabolism, enables a sensitive and specific detection of AD in its early 
stages. A reduce of glucose metabolism in bilateral temporal parietal regions and in the posterior 
cingulate cortex is the most commonly described diagnostic criterion for AD. PET with Aβ ligands, 
such as 11C-labelled Pittsburgh compound B (PiB) and an 18F-labelled Aβ ligand, can be used to 
directly visualise Aβ in vivo. The 11C-PiB binding sites in brain are associated with Aβ sheets in 
neuritic and diffuse plaques, as well as CAA, it does not bind to soluble and oligomeric amyloid 
[7,27]. 
The SPECT comprises a radioisotopic scan accomplished with single-proton emission CT (SPECT), 
and is a useful neuroimaging technique for distinguishing AD from FTLD. Ligands have also been 
developed that visualise specific neurotransmitter systems with SPECT [7].  
Ultrasound and optical imaging are the next promising techniques that can replace high energy 
radioisotopes and cost effective instruments largely employed in clinical settings. It could be 
possible to combine development of deep tissue multiphoton imaging systems with optical imaging 
to generate fusion image with better resolution. Besides, development of new molecular imaging 
technologies should use neurochemical biomarkers to detect the earliest AD pathogenic events, 
improve classification, track progression and assess in prediction [19].  
 
5.3. Neuropsychological evaluation 
Neuropsychological characterization remains essential to understanding individual deficits, 
contributing for nonpharmacologic interventions properly applied [33]. Several measures have 
been developed for helping to determine dementia severity, such as mini-mental state examination 
(MMSE) and clinical dementia rating scale (CDR) [34]. Other tests could be used: ADAS-Cog 
(Alzheimer’s Disease Assessment Scale-Cognitive), considered more thorough than MMSE and 
focusing on language, orientation, executive functioning and memory skills; MoCA (Montreal 
Cognitive Assessment), that includes a clock-drawing test and a test of executive function, it is 
relatively simple and very useful; Clock Drawing Test, often used combined to other tests, it assess 
visual-spatial impairment, memory and executive functions; CANTAB (Cambridge 
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Neuropsychological Test Automated Battery), it consists in 13 interrelated computerized tests of 
memory and executive functioning and it appear to be quite sensitive to AD warning signs and 
relatively unbiased regarding culture issues [34,35].   
MMSE is the most commonly used test for complaints of memory problems, helping clinicians in 
dementia diagnosis as well as assessing its progression and severity. It consists of a series of 
questions and tests with a possible total score of 30 points (Table 4). Different mental abilities are 
evaluated, including memory, attention and language. On average, AD patients who are not 
receiving treatment lose two to four MMSE points each year. It is important to note that some 
factors might influence MMSE total score, such as educational and cultural issues, mental 
impairment by another reason does not dementia, difficult hearing [36,37].  
 
Table 4|Interpretation of MMSE scores, with correspondence to degree of impairment and need to proceed 
to a formal psychometric assessment. 
Score Degree of Impairment Formal Psychometric Assessment 
25-30 Questionably significant Only if clinical signs of cognitive impairment are present 
20-25 Mild To better determine pattern and extent of deficits 
10-20 Moderate If there are specific clinical indications 
0-10 Severe Patient not likely to be testable 
 
CDR is comprised of six cognitive and functional domains (memory, orientation, judgement and 
problem solving, community affairs, home and hobbies, personal care), which clinicians fulfil based 
on interview data from patient and a collateral source (e.g. caregiver) [34].  
 
5.4. Differential Diagnosis 
NINCDS-ADRDA criteria have been validated against neuropathological gold standards with 
diagnostic accuracy from 65-96%. However, specificity of these criteria against other dementias is 
only 23-88%. Currently criteria (1997 NIA/Reagan criteria) for neuropathological diagnosis of AD 
need to be updated trough improvement in definition and characterisation of non-AD dementias, 
since their methods are not robustly quantitative and/or not systematically qualitative [30,38].  
In clinical practice it is often difficult to recognize each type of dementia, and to define landmarks 
that differentiate dementia from the mild decline in memory and cognitive function seen during 
aging. Following AD, the most common neurodegenerative dementias (Table 5) are frontotemporal 
lobar degeneration (FTLD), vascular dementia (VaD), dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD) [5,11]. 
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Table 5| Main neuropathological characteristics of the most common neurodegenerative dementias besides 
AD.  
Disease Main clinical, imaging and histopathological findings Refs 
AD Hallmark lesions: Aβ extracellular deposition (amyloid plaques) and 
intracellular neurofibrillary tangles (accumulated p-tau)  
Clinical: prominent episodic memory impairment, with secondary deficits in 
word-finding skills, visual-spatial cognition and executive functions; common 
neuropsychiatric symptoms and personality alterations 
Imaging: PiB-PET positive amyloid tracer in prefrontal, medial parietal, lateral 
temporal and posterior cingulate cortices, and striatum; FDG-PET shows 
hypometabolism in posterior cingulate and temporo-parietal cortices; 
disproportionate atrophy on MRI in medial, basal and lateral temporal lobe, 
and medial parietal cortex 
[4,39] 
FTLD Hallmark lesions: cellular inclusions constituted by MAPT (FTLD-tau), TDP-43 
(FTLD-TDP) and FUS (FTLD-FUS) 
Clinical: progressive non-fluent aphasia (FTLD-tau), semantic dementia and 
motor neuron disease (FTLD-TDP), behavioural perturbations (FTLD-FUS); 
inefficient retrieval strategies; onset usually before 65 years old 
Imaging: structural MRI changes and salient hypometabolism in left perisylvian 
language regions (FTLD-tau and FTLD-TDP); atrophy and hypometabolism at 
bilateral frontal and anterior temporal areas (FTLD-FUS) 
[4,11,32,39] 
VaD Hallmark lesions: multiple or strategically placed infarctions, ischemic brain 
injury and haemorrhagic lesions 
Clinical: relative abrupt onset, fluctuating cognition (often mild symptoms) 
related to stroke(s); executive dysfunction and focal neurological signs; 
depression, psychomotor retardation and affective disorders 
Imaging: widespread vessel disease on MRI 
[5,32,39] 
DLB Hallmark lesions: α-synuclein deposits (Lewy bodies and Lewy neurites)  
Clinical: dementia with ADL impairment; fluctuating cognition (especially 
attention and awareness); recurrent visual and auditory hallucinations, 
delusions and transient loss of consciousness; symptoms of Parkinson’s 
disease; REM sleep behaviour disorder and depression 
Imaging: SPECT or PET scan shows reduced dopaminergic activity in basal 
ganglia, hypometabolism and hypoperfusion in primary and association visual 
cortices  
[4,32,39,40] 
PDD Hallmark lesions: α-synuclein deposits (Lewy bodies and Lewy neurites)  
Clinical: Queen Square Brain Bank criteria* for Parkinson’s disease; impairment 
of more than one cognitive domain affecting ADL (mainly executive and visual-
spatial functions, memory and speech); apathy, personality and mood 
alterations; hallucinations and delusions; increased daytime fatigue 
Imaging: MRI volumetry shows atrophy of basal ganglia, hippocampus, 
parahippocampal regions and anterior cingulate gyrus; SPECT or PET scan 
shows reduced dopaminergic activity in basal ganglia 
[4,40,41] 
MAPT: microtubule associated protein; TDP-43: transactive response DNA binding protein of 43 kD; FUS: fused 
in sarcoma protein 
*Clinical criteria according to which, for a diagnosis of Parkinson’s disease, it has to be present bradykinesia 
and at least one of the following symptoms: muscle rigidity, resting tremor, and/or postural instability; 
besides presence of supporting criteria (e.g. unilateral onset) and absence of exclusion criteria (e.g. no 
improvement after levodopa treatment).   
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Depression is a significant health problem among elderly population which can be accompanied by 
a pseudodementia state that is often included in differential diagnosis of dementia, since many of 
the features of an early dementia are apparent, especially memory impairment, slowed thinking 
and lack of spontaneity. However, patients with pseudodementia often have a previous history of 
depression or a family history of mood disorder, whose successful treatment restores intellectual 
function, unlike what happens with dementia [5,6]. Besides, contrarily to dementia, 
pseudodementia has rapid onset and relatively short symptomatology duration, patient might 
display marked variability in performing tasks of similar difficulty or may lack of interest in 
answering questions, further neurologic symptoms are not present [6]. 
 
6. ALZHEIMER’S TREATMENT AND THERAPEUTIC PERSPECTIVES  
6.1. Pharmacological treatment   
Several drugs have become available over the past two decades to help further cognitive decline in 
AD [6]. However, AD is reaching epidemic proportions, with a large human, social and economic 
burden, for which effective treatments are greatly needed. Current drugs for AD target cholinergic 
and glutamatergic neurotransmission, thus improving symptoms, although their neuroprotective 
activity is still debated. Much effort is directed towards identifying disease-modifying therapies, 
with several compounds in different phases of development and being subject of clinical trials [43]. 
 
6.2. Targeting cholinergic and glutamatergic neurotransmission 
Cholinergic neurons are selectively (>70%) degenerated in AD, with the loss of cholinergic function 
being closely related to cognitive dysfunction. Therefore, therapeutics emphasis has been on 
increasing cholinergic synaptic transmission in areas of the brain that are concerned with memory 
and cognition. Acetylcholinesterase inhibitors (AChEIs), that inhibit the breakdown of acetylcholine 
released by still-intact neurons, are considered the best developed therapy   stabilizing cognitive 
decline for up to 3-6 months, which corresponds to 1,5 - 2 points on the MMSE over 6-12 months. 
Moderate improvements in mood and social interaction have also been reported. However, no 
modification of disease duration or general disease progression has been accomplished, since they 
are not actually considered modifying-disease drugs, only symptomatic relievers. Currently, three 
AChEIs – donepezil, rivastigmine and galantamine – are available as cognitive-enhancing agents 
(Table 6) [6,7,9].  
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Table 6|Currently approved drugs for treatment in AD. Adapted from [9,10,42].  
Drug Disease stage Symptomatic activity Potential neuroprotective activity 
AChEI 
Donepezil 
(Aricept®) 
All stages AChEI Possibly decreases levels of APP, production of 
Aβ and other amyloidogenic compounds, and  
Aβ-induced toxicity; modulates expression of 
AChEI isoforms; increases expression of 
nicotinic receptors 
Rivastigmine 
(Exelon®) 
Mild to 
moderate 
AChEI and BChEI 
Galantamine 
(Razadyne®) 
Mild to 
moderate 
AChEI 
(nicotinic receptor 
modulation) 
NMDA receptor antagonist 
Memantine 
(Namenda®) 
Moderate to 
severe  
Uncompetitive, 
voltage-dependent 
NMDA receptor 
antagonist 
Decreases Aβ toxicity; prevents 
hyperphosphorylation of tau; decreases 
microglia-associated inflammation; increases 
release of neurotrophic factors from astroglia 
BChEI: butyrylcholinesterase inhibitor; AChEI: acetylcholinesterase inhibitors; NMDA: N-methyl D-aspartate 
 
There is evidence that combine therapy of memantine with an AChEI, namely donepezil, may 
provide better outcomes with regards to cognition, ADL, global outcome and behaviour [7,9]. 
Direct activation of postsynaptic cholinergic receptors by muscarinic agonists may decrease 
secretion of Aβ and increase secretion of nerve growth factor (NGF). In this insight, other 
substances besides rivastigmine that are capable of blocking butyrylcholinesterases, nonsynaptic 
(nonspecific) cholinesterases, are being explored [9]. 
6.2.1. Researching possible disease-modifying therapies 
Apart from the ACIs already approved there has been little development of cholinergic drugs. 
Besides this drug category, other ones are being focus in drug development and research (Table 7), 
such as non-cholinergic modifying neurotransmission drugs, anti-amyloid therapies, drugs to target 
tau protein, targeting mitochondrial dysfunction therapies, neurotrophins, and other potential 
therapeutic strategies (e.g. antioxidant supplementation) [43].  
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Table 7| Main anti-AD drug categories that are being focus in drug research. Adapted from [15,43,44]. 
Anti-amyloid therapies  
AD drug development is driven mainly by the amyloid hypothesis, thus most of clinical trials are 
designed to target Aβ. 
Targeting of Aβ production 
β-secretase inhibitors 
Their development is challenging, since this enzyme has many substrates and a wide substrate binding 
domain. Furthermore, candidate drugs must cross the blood-brain barrier. Oral drugs for Type II DM, 
rosiglitazone and pioglitazone, act as β-secretase inhibitors by stimulating PPARγ. However, it was reported 
in clinical trial environment that there was no efficacy on cognition or global function, besides FDA warning 
for possible cardiac risks associated with the use of rosiglitazone. 
γ-secretase inhibitors and modulators 
Besides similar challenges presented to those for β-secretase inhibitors, this drug category are associated 
to collateral effects caused mainly by inhibition of Notch signalling pathway, which is involved in cell 
differentiation.  
α-secretase activators 
Several drugs have been tested in clinical trials, but no evidence supports their use in AD yet.  
Targeting of Aβ aggregation 
Peptidic and non-peptidic anti-aggregants have been tested, with promising results particularly 
from PBT2, that it was subject of a 12-week phase 2 RCT with mild AD patients. 
Targeting of Aβ clearance 
Apart from advantages and disadvantages of immunization strategies, evidence suggests that 
clearance of amyloid plaques alone cannot repair already damaged neurons and prevent disease 
progression.  
Drugs to target tau protein 
The only one tau-directed compound (valproate) that has reached phase 3 RCT presented 
disappointing results since there were no effects on cognition and functional status. More 
compounds that target tau-phosphorylating kinases, to prevent tau aggregation or to promote 
aggregate disassembly, are in development.  
Targeting mitochondrial dysfunction therapies 
A new approach to AD therapy, different from the protein-focused strategies that currently 
dominate research, since it is thought that mitochondrial dysfunction have a causal role in 
neurodegeneration. Although some promising results from phase II RCTs with latrepirdine, a non-
selective antihistamine, phase III CONCERT trial presented in 2012 had disappointing results, 
leading to discontinuation of latrepirdine development for all indications.  
Neurotrophins 
Basal forebrain cholinergic neurons depend on NGF for survival and fibre outgrowth. 
Furthermore, recent findings have suggested a causal link between NGF imbalance, activation of 
amyloidogenic pathway and AD neurodegeneration. Several clinical trials with NGF delivery have 
been made and some are ongoing, particularly using gene therapy, but further research is 
needed.  
Other potential therapeutic strategies 
Other approaches such as omega-3 polyunsaturated fatty acids (e.g. docosahexaenoic acid), 
antioxidants (e.g. vitamin E), NSAIDs, statins or drugs that target phosphodiesterase have been 
tested in RCTs, some of them are ongoing. However, without much promising results yet.  
 
 
 
  28  
 
Antioxidant supplementation is still a matter of discussion since high doses of vitamin E have been 
associated with increased mortality risk and no beneficial effects for AD patients, whereas it is 
thought that a combination of micronutrients could be more effective in neuroprotection [6,42]. 
Further, a more recent RCT in MCI patients did not report any benefit with vitamin E [7].  
 
6.3. Non-pharmacological therapy 
Over the 8 to 10 years of progressing dementia, patients became increasingly disabled in ADLs.  
Physical therapy can improve mobility despite the dementia. The approach to ADLs and social 
activities must take advantage of the ability of many AD patients to learn skills through procedural 
memory. This motor learning depends upon corticocerebellar and striatal structures, rather than 
upon the mesial temporal neural networks that bear the brunt of neurodegeneration. It has been 
already shown that motor learning and the transfer of motor skills requires constant practice for 
AD patients, for which is thus essential consistent repetition without interference to optimize 
learning. Without specific practice, 30% of patients deteriorated in ADLs such as walking, eating, 
dressing and continence [45].  
Cognitive training in healthy older people and in patients in early stages of AD might also be helpful 
by improvising specific aspects of cognitive ability, with a recent meta-analysis and systematic 
review suggesting moderate benefit across a variety of training approaches [7]. 
 
7. BIOMARKERS IN AD DIAGNOSIS  
As aforesaid, diagnostic criteria currently used for AD are based on clinical features supporting a 
probabilistic diagnosis with low specificity, particularly when these criteria are applied at very early 
stages of disease or used to monitor effects in drug development research. Moreover, 
symptomatology required for diagnosis is evident only a long time after initiation of pathological 
process, and since therapies are initiated only after diagnosis their modest benefit may be 
explained, in part, by the fact that some irreversible brain damage has already occurred at this time 
[46]. Hence, it has been emphasized the importance for new AD diagnosis criteria on defining 
preclinical AD and MCI phases, allowing to initiate a more earlier therapeutic intervention [26]. 
Indeed, the discovery of an effective treatment in the preclinical phase would in fact be a preventive 
therapy, though secondary prevention [2].  
Discovery of new AD biomarkers is then essential for developing disease-modifying therapies and 
potentially reducing costs of clinical trials. In that way, new biomarkers are needed for early 
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diagnosis, ideally even before cognitive symptoms arise (sensitive biomarkers); accurate diagnosis, 
differential diagnosis between several kinds of dementia (specific biomarkers); and measurement 
of disease progression within the time of a clinical trial that could measure pathology directly or 
indirectly (surrogate biomarker) [2]. Further regarding clinical trials, biomarkers should facilitate 
selection of drug candidates, verify the mechanism of action, define dose effects, and thus diminish 
length and sample size of clinical trials [27].  
Following this thoughts sequence, new AD biomarkers will need to be reliable (robust against main 
confounding factors such as age, gender and genotype), reproducible, easily obtainable, non-
invasive, well-validated, more constant as possible throughout time in healthy people, and presents 
little variation due to unrelated comorbidities [2].  
Furthermore, an accurate diagnosis of dementia enables detection of potentially treatable 
disorders that contribute to cognitive impairment, such as depression, vitamin deficiencies and 
hypothyroidism [7].  
 
7.1. Current used AD biomarkers 
The five most widely studied AD biomarkers corresponds to Aβ42 and tau (total and phosphorylated 
form) levels in CSF, fluorodeoxyglucose uptake pattern on PET (FDG-PET), amyloid PET imaging (11C-
PiB), and structural MRI measures (Table 8). Each of them is well validated enough to be 
incorporated into AD renewed diagnosis criteria and used in therapeutic trials and large 
observational studies. Both CSF Aβ42 and amyloid PET imaging are biomarkers of Aβ plaque 
deposition, while the others are related to neurodegeneration [20,29,45].  
 
Table 8| Currently used AD biomarkers, according to NINCDS-ADRADA revised criteria and based in recent 
evidences. 
Biomarker Biomarker alteration in AD 
Aβ plaque deposition/accumulation biomarkers 
amyloid PET imaging 
abnormal tracer retention (11C-PiB specifically binds to fibrillar Aβ, 
and not to soluble Aβ or to diffuse plaques) 
[CSF Aβ42] low levels 
Biomarkers of neuronal degeneration or injury 
[CSF tautotal and p-tau] high levels 
FDG-PET 
decreased fluorodeoxyglucose uptake in a specific pattern involving 
temporoparietal cortex 
Structural MRI 
Atrophy specific pattern involving medial, basal and lateral temporal 
lobes, besides medial and lateral parietal cortices 
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The onset and progression of AD biomarkers appear to follow an ordered temporal pattern (Figure 
6). Aβ biomarkers are indicative of initiating or upstream events which seem to be most dynamic 
before clinical symptoms appear, it has been suggested that they may become abnormal even 10-
20 years before noticeable clinical symptoms. In other hand, biomarkers of neuronal injury and 
dysfunction are indicative of downstream pathophysiological processes which become dynamic 
later, with some studies suggesting that it might occur shortly before first symptoms arise. Besides, 
symptomatology progression closely parallels progressive worsening of neurodegenerative 
biomarkers [47].  
 
 
Figure 6|Chronobiological representation of AD biomarkers dynamic according to clinical disease stage 
progression. Each biomarker is represent by a different colour, correspondence in right board. Adapted from 
[19]. 
 
 
The temporal lag between AD pathological process appearance and emergence of AD associated 
clinical syndromes may be influenced by factors such as brain or cognitive reserve, besides 
aforesaid main risk factors [48]. 
FDG-PET, tau-CSF and volumetric MRI may be more pertinent biomarkers than Aβ-CSF PET at 
distinguishing early till late MCI. As cognitive behaviour alterations increase between early and late 
MCI and further progress during advance AD stage, volumetric MRI remains at present the sole 
biomarkers measuring differentially those alterations [19].  
As aforesaid, in the preclinical phase, biomarkers are used to establish the presence of AD 
pathophysiology process in research subjects with no or very subtle overt symptoms. According to 
abovementioned biomarkers pattern (positive for presence and negative for absence of biomarker 
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alteration/abnormality), preclinical phase can be divided into three different stages (Table 9), 
currently for research proposes [45,46].  
 
Table 9| Staging categories for preclinical AD research, with an important role of biomarkers. Adapted from 
[48]. 
 
Stage Description Aβ  
(PET/CSF) 
Tau, sMRI, 
FDG-PET 
Subtle cognitive 
change 
Stage 1 Asymptomatic cerebral amyloidosis + - - 
Stage 2 Stage 1 + “downstream” neurodegeneration + + - 
Stage 3 Stage 2 + subtle cognitive/behavioural decline + + + 
sMRI: structural magnetic resonance 
 
In MCI phase, biomarkers are used to establish the underlying etiology responsible for the clinical 
deficit. Besides biomarker severity, particularly neuronal injury biomarkers, indicates likelihood of 
imminent progression to AD dementia. In turn, at dementia phase, biomarkers are used as an 
attempt to increase certainty level that AD pathological process underlies the presented dementia 
[47].  
 
7.2. Fluid AD biomarkers and further challenges 
7.2.1. CSF biomarkers 
CSF may be considered an ideal source for viable AD biomarkers, since it is in intimate contact with 
cerebral tissue and pathological brain alterations are often reflected in CSF. The obtained pattern 
of CSF concentrations of Aβ42, total tau and phosphorylated tau in AD is commonly known as the 
“AD signature” in CSF (Table 10), which has good diagnostic accuracy to distinguish between normal 
aging and AD (>85%) and a predictive value (>90%) to determine dementia outcome in MCI 
patients. However, this predictive value becomes lower as patients get older, and its 
sensitivity/specificity is significantly lower at differentiate AD from other dementias (especially total 
tau whose increase is frequently observed in other diseases). The rates of change in total tau/Aβ42 
and p-tau/Aβ42 ratios are considered more powerful predictors, rather than one of these 
measurements alone [47,48].  
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Table 10|Levels of core AD biomarkers in CSF. Adapted from [49]. 
[CSF] (pg/mL) Reference range AD 
Aβ42  > 550 365-535 
total tau  <375 419-860 
p-tau  <52 63-112 
 
ELISA is one of the most common assays for measuring CSF concentration of these three core AD 
biomarkers. Besides Aβ42 form, it is also possible ELISA measurement of truncated Aβ42 fragments; 
all tau isoforms are detected, independently of phosphorylation state; most common measured p-
tau are that is phosphorylated at residue 181 or 231. It has been developed multiparameter 
platforms based on xMAP® technology for simultaneous measurement of these biomarkers, 
however there are some drawbacks associated with these assays [48,49]. 
Besides from diagnosis, CSF biomarkers may be used for prognosis, assessing disease progression, 
developing treatments, monitoring treatment effects and studying disease mechanisms. Several 
analytes related to Aβ have been investigated as potential AD biomarkers, such as BACE1, 
sAPPα/sAPPβ and Aβ oligomers. It is though that these oligomers might be more toxic than fibrillar 
Aβ aggregates, they are able of inhibit hippocampal long-term potentiation and cause abnormal 
tau phosphorylation and neuritic dystrophy [50].  Recently it was developed a new technique, 
protein misfolding cyclic amplification assay (Aβ-PMCA), which allows detection of as little as 3 fmol 
of Aβ oligomers in CSF. This provides the proof-of principle basis for developing a highly sensitive 
and specific biochemical test for AD diagnosis, not only for Aβ oligomers detection in CSF, since 
detecting Aβ oligomers that may potentially be circulating in blood of AD patients might offer a 
great opportunity for more-routine testing [51].  
There are several other interesting candidate CSF biomarkers associated to inflammatory response 
in AD, influence of cholesterol metabolism in pathological process, and endosomal vesicle recycling 
in affecting neurons [50].  
7.2.2. Blood biomarkers 
Although CSF represents the most suitable biological fluid to study neurodegenerative diseases 
since it can reflect the biochemical changes occurring in brain, its analysis is not always easily 
feasible for a large scale screening, because of the huge economic costs and procedures that are 
invasive, uncomfortable and not without risk. Thus, for a full screening and early diagnosis, 
biomarkers easily detectable in biological samples, such as plasma, are needed. Blood-based 
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biomarkers are minimally invasive and could increase diagnostic accuracy, be useful for prognosis 
and in monitoring therapeutic interventions [46].  
Several biomarkers based on plasma proteins have been investigate through multiplex or 
proteomics approaches. None have yet been tested in phase 3 trials, but promising findings have 
been reported for complement factor H, alpha-2-macroglobulin and clusterin [7]. 
The valosin-containing protein (p97) is an ubiquitin-dependent ATPase with central role in ubiquitin 
proteasome system (UPS)-mediated protein degradation pathways. The p97 cleavage by caspase-
6 (Casp6), which is a putative effector of AD neurodegeneration, has been related to UPS 
impairment. Indeed, Casp6 activation positively correlates with cognitive decline in aged individuals 
and occurs at all AD stages. It is thought that Casp6 may exacerbate ubiquitinated proteins 
accumulation through proteolytic processing of p97 [52]. Moreover, p97 soluble form has been 
suggested to be increased in blood of AD patients, although further studies are needed to confirm 
p97 as a reliable marker of AD [53].  
It is important to note that only small hydrophobic, lipophilic molecules are more easily transported 
from CSF into blood, through BBB. This implies that the most relevant markers will be in low 
abundance in plasma, at least in normal healthy people. Nevertheless, there is increasing evidence 
for a compromised BBB in neurodegeneration, which will impact on the type of molecules leaking 
out of brain into blood circulation [2].   
7.2.3. Main challenges for AD biomarkers research and development 
Peripheral sources of biomarkers (plasma, serum, urine and saliva) present considerable 
advantages, such as easier collection, cheaper proceeding and repeated samplings can be 
performed for regular monitoring. However, these sources are further away from the brain. This 
implies peripheral markers will need to be correlated with accepted markers of AD pathology 
(observed in brain and CSF), to demonstrate that they reflect AD pathology [2]. Besides, these 
markers need to be determined as to whether they can be influenced by other organ systems, since 
AD patients also typically present comorbidities due to aging [54].  
Besides all the potentiality of fluid biomarkers, there are some associated limitations, mainly the 
lack of anatomical precision in measurements and the lack of assay standardization. Thus, extensive 
standardization of every aspect of biomarkers analysis is now being addressed through initiation of 
an international quality-control program, which includes CSF reference materials and in the 
European Joint Programming project “Biomarkers for Alzheimer’s disease and Parkinson’s disease” 
(BIOMARKAPD) [48,49]. Besides, work to validation of both fluid-based and imaging biomarker 
thresholds is ingoing [48]. 
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Other challenge for biomarkers research is the substantial overlap of major brain pathologies. Thus, 
a better understanding of how combinations of pathologies affect changes in biomarkers is needed 
[7]. Indeed, powerful and innovative bioinformatics tolls are be needed to unravel multivariate 
plasma AD signatures [2]. 
 
8. STRATEGIES FOR BIOMARKERS RESEARCH IN NEUROLOGICAL PATHOLOGY    
Up to now, most of efforts in discovering new AD biomarkers have focused on measuring changes 
either directly in the brain or in cerebrospinal fluid (CSF). Although both PET and CSF analyses are 
very promising AD markers with potential for clinic application, they are respectively costly and 
sparsely available or evolve invasive procedures, besides neither is amenable to repeated sampling 
that is an important aspect of a biomarker's role and utility. Besides, these markers have not yet 
been shown to adequately predict early diagnosis or disease progression [2]. 
In the past decade, genomics has been used on identifying susceptibility AD factors. However, while 
risk genetic traits are important for identification they cannot be markers of disease state. Thus, for 
a true state marker other "omics" are needed, namely proteomics (related to protein translation, 
inclusive post-translational modifications), transcriptomics (measurement of mRNA levels for 
quantifying gene expression) or metabolomics (identification and/or quantitation of metabolites in 
a given biological sample) [2,55].   
Biomarker discovery tends to take one of two options: target approach, which is hypothesis based 
and designed to investigate a specific molecule or group of molecules; nontargeted approach, using 
an unknown hypothesis and designed to analyse a large number of molecules in an unbiased 
manner. Within targeted approaches, commonly used techniques are nuclear magnetic resonance 
(NMR) and MRS, multiple mass spectrometry (MS)-based methods, and immunoassays (e.g. ELISA). 
Since there is an increasing trend for biological samples to be analysed without a specific target 
molecule, within nontargeted approaches metabonomics and metabolomics fields have been 
expanding, as it seen ahead. Besides, nontargeted approaches improved analytical equipment and 
data models make these a valuable alternative [56]. 
Proteomic technologies introduced the concept of a blood signature, arguing that a combination of 
plasma biomarkers (i.e. a signature) rather than a single marker will be needed to reflect the 
complexity of AD pathology [2]. Besides, proteomics has garnered recent attention mainly because 
proteins are readily available in body fluids and are more stable than mRNA and metabolites. This 
“omic” studies both structure and function of proteins by several methods, whether qualitative or 
 
  35  
 
quantitative, allowing to reveal static or perturbation-induced changes in a protein profile [54]. 
Proteomics provides an unbiased approach to detecting protein biomarkers in complex sample 
mixtures such as plasma. It uses MS data coupled with protein database pattern recognition search 
algorithms to identify large numbers of proteins simultaneously. One of the most powerful protein 
identification strategies is liquid chromatography (LC) separation followed by MS analysis, usually 
ESI (electrospray ionization). Few studies have used proteomic methods to new AD plasma 
biomarkers discovery, making neuroproteomics an emerging technology. The plasma proteins that 
have been identified by these techniques are related with lipid or other molecules transportation, 
immune regulation and inflammation [57]. 
Moreover, it has been developed a new field called peptidomics, a proteomics analysis of peptides 
and small proteins, since proteins can be cleaved aberrantly (e.g. APP cleavage by α and β-
secretases) direct de novo analysis of endogenous peptides could be invaluable for disease 
diagnosis [54].  
 
8.1. Metabolomics approaches in biomarker identification   
Although still a relatively nascent field, metabolomics is being developed and applied as a more 
global approach to neurodegenerative disorders biomarkers discovery. Metabolomics is now 
commonly defined as the detection and quantitation of all low-molecular-weight molecules and 
metabolites present in cells, tissues or organisms under a set of given conditions. Thus, it is able of 
quantify metabolite changes indicative of alterations in anabolic and catabolic processes in a given 
individual. In turn, metabonomics is described as the quantitative analysis of metabolic response of 
living systems to pathophysiological stimuli or genetic modification over time [2,55].  
The metabolome is the collection of small molecules that are found within a biological system and 
whose identities, concentrations and fluxes are the final product of interactions between gene and 
protein expression, and the cellular environment. Thus, metabolomics information complements 
the obtained data from genomics, transcriptomics and proteomics [58].  
Metabolomic techniques have been used to identify biochemical pathways perturbations related 
to several diseases, either in biological fluids (plasma, urine and CSF), animal models, and tissue or 
cell cultures [58]. Recently, several metabolic diseases such as diabetes, dyslipidaemia and 
hypertension have been associated with AD and progression of MCI to dementia phase. 
Additionally, several metabolic enzymes of the glycolytic, tricarboxylic and acid cycle and oxidative 
phosphorylation pathways are known to be impaired in AD, and pharmacological inhibition of 
metabolism further exacerbates AD pathology. Therefore, metabolic dysfunctions identification 
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using an unbiased metabolomics approach could provide a more comprehensive picture of the 
pathways involved in AD [26].  
A typical metabolomics study includes four main steps: uniform sample collection, sample analysis 
(e.g. NMR, MS), statistical analysis (e.g. PCA, PLS-DA), and identification of significantly altered 
metabolites that could be translated into new disease biomarkers/pathways [26]. The main 
metabolic fingerprinting approaches used for disease diagnostics includes infrared and Raman 
spectroscopy, NMR and MS-based methods. Hence the multiple advantages and more widespread 
use of infrared spectroscopy, its role in metabolomics will be emphasized ahead [55].  
One of the main metabolomics challenges is the development of standard protocols regarding 
sample collection and storage, chemical analyses, data processing, and information exchange. 
Indeed, it was already created the Metabolomics Standard Initiative (MSI), with support of the 
Metabolomic Society, to recommend standard protocols for use in all aspects of metabolomic 
research [58]. 
 
8.2. Potential of FTIR spectroscopy as metabolomics research tool   
Fourier transform infrared (FTIR) spectroscopy has a significant and ongoing history of research into 
its potential as a diagnostic tool and allows for the extremely rapid, high-throughput and non-
destructive analysis of a wide range of sample types. It uses vibration frequencies of molecules 
present in the analysed sample to produce a metabolic fingerprint, which is then specific for each 
sample. In terms of disease diagnosis, much of the work undertaken has concentrated on the mid-
infrared (IR) region of electromagnetic spectrum (from 4000-600 cm-1 of wavelength). Although 
FTIR has been recognized as not as specific and sensitive as some of the MS-based techniques, the 
rapidity and reproducibility of FTIR is demonstrable through the extensive number of published 
research using this technology. Besides, it has been recognized as a valuable tool for metabolic 
fingerprinting as it is able to analyse carbohydrates, amino acids, fatty acids, lipids, proteins, nucleic 
acids and polysaccharides simultaneously with a minimum amount of sample preparation. Indeed, 
besides its rapidity (<10 seconds per sample is readily achievable), FTIR is an ideal candidate 
technology for high-throughput screening as it is possible to measure thousands of samples per day 
and obtain information-rich spectra using as little as 0,5 μl of sample. Also, FTIR is less expensive 
and more accurate rather other methods  [55,59]. 
FTIR has been used in several pathology research fields besides neurodegenerative diseases, 
including oncology. Indeed, FTIR has been identified as an emergent technology in cervical cancer 
screening, and at differentiation between benign and malignant prostatic epithelium (i.e. 
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differentiate BPH from prostatic cancer). Besides, further studies have been undertaken on a range 
of cancers including breast, brain, bladder, thyroid tumours, colorectal adenocarcinoma sections, 
larynx, oesophagus and gastric cancer [55]. 
 
9. SIGNIFICANCE OF THE STUDY 
AD is the most common and debilitating neurodegenerative disease among older population, with 
number of worldwide affected people prone to rise significantly giving the higher population aging. 
With no sufficiently accurate diagnosis in an earlier disease stage, nor either a disease-modifying 
therapy available, AD severely affects daily living of patients and their relatives. Besides the 
dramatic human suffering and loss, AD translates in a huge economic burden for countries health 
systems. Thus, it is sorely needed a simple, accurate and cost-effective early AD diagnosis in order 
to treat and even prevent first signs of disease, with introduction of reliable therapeutic 
approaches.            
Hence, the main aims of this study pass through FTIR analysis of plasma samples, from both healthy 
(control) and putative AD (disease) subjects; identification of the main metabolic characteristics 
present in obtained FTIR spectra, inquiring if they could be related to AD pathology; differentiation 
of samples in groups (e.g. control vs AD) through data multivariate analysis, allowing not only to 
compare between groups but also to compare between samples of the same group; and 
identification of the more significant altered metabolites and their eventual role at the disease 
context.  
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1. FTIR METHOD OVERVIEW  
1.1. Fundamental principles  
Fourier transform infrared spectroscopy (FTIR) is a type of infrared (IR) spectroscopy, and it 
constitutes the absorption measurement of different IR frequencies by a sample positioned in the 
path of an IR beam, some of this radiation is absorbed by the sample and some of it is passed 
through (transmitted). The resulting spectrum represents molecular absorption and transmission, 
creating a molecular fingerprinting of the analysed sample. In spectrum, absorption peaks 
correspond to the frequencies of vibrations of sample chemical bonds, allowing to identify sample 
functional groups and/or elucidate molecular structure (qualitative analysis); besides, the size of 
these peaks is correlated with the amount of each functional group (quantitative analysis). Through 
utilization of several sampling accessories, IR spectrometers are able to analyse a wide range of 
sample types such as gases, liquids and solids [60,61]. 
IR spectral region (Figure 7) ranges from the red end of visible spectrum at 780 nm (12820 cm-1 of 
wavenumber) to the onset of microwave region at a wavelength of 1 mm (10 cm-1). In turn, IR range 
is further subdivided into the near-infrared (NIR), mid-infrared (MIR) and far-infrared (FIR) regions. 
MIR covers the range 4000-400 cm-1 and is the region that usually provides the fingerprint 
characteristics of molecular species. Besides, MIR includes the rich absorptions spectrum 
corresponding to fundamental vibrations of the species being probed. MIR absorption positions are 
reported in units of wavenumbers (cm-1, the inverse of wavelengths in centimetres) [62]. 
 
 
Figure 7| The electromagnetic spectrum, with IR region magnified. Adapted from [63,64]. 
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1.2. Vibration of molecules 
The energy possessed by a molecule at any given moment is defined as the sum of contributing 
energy terms: translational energy, related to the molecules displacement in space as a function of 
normal thermal motions of matter; rotational energy, the tumbling motion of a molecule which 
results from the energy absorption within the microwave region; vibrational energy, which is a 
higher energy term and corresponds to the energy absorption by a molecule as the component 
atoms vibrate about the mean centre of their chemical bonds; electronic energy, which is linked to 
energy transitions of electrons as they are distributed throughout the molecule [65]. IR radiation 
does not have enough energy to induce electronic transitions as seen with ultraviolet (UV) 
radiation. Absorption of IR is restricted to compounds with small energy differences in the possible 
vibrational and rotational states. The fundamental requirement for IR activity and consequent IR 
absorption by molecules is that vibrations or rotations within a molecule must cause a net change 
in the molecule dipole moment. It is known that the alternating electrical field of radiation interacts 
with fluctuations in the molecular dipole moment. If radiation frequency matches vibrational 
frequency of the molecule then radiation will be absorbed, leading to a change in molecular 
vibration amplitude [66]. In general, the larger the dipole change, the stronger the band intensity 
in the IR spectrum [67].  
Rotational transitions are of little use to posterior FTIR spectrum interpretation. Rotational levels 
are quantized and IR absorption by gases yields line spectra; however, in liquids or solids, these 
lines broaden into a continuum due to molecular collisions and other interactions [66].  
 
Each atom has three degrees of freedom, corresponding to motions along any of the Cartesian 
coordinate axes (x, y, z), thus a polyatomic molecule of n atoms has 3n total degrees of freedom. 
Nevertheless, 3 degrees of freedom are required to describe translation, and other 3 correspond 
to rotation of the entire molecule. Thus, the remaining 3n-6 degrees of freedom are fundamental 
vibrations for nonlinear molecules, while linear molecules possess 3n-5 fundamental vibrational 
modes since only 2 degrees of freedom are sufficient to describe rotation. Among the 3n-6 or 3n-5 
fundamental vibrations, also known as normal vibration modes, those that produce a net change 
in the dipole moment may result in an IR activity and those that give polarizability changes may give 
rise to Raman activity. Indeed, some vibrations can be both IR and Raman active [61].  
Therefore, atomic positions in molecules are not fixed, since they are subject to several vibrations. 
The major types of molecular vibrations (Figure 8) are stretching, change in inter-atomic distance 
along bond axis; and bending, change in angle between two bonds, that present four different types 
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(i.e. rocking, scissoring, wagging and twisting) [66]. Bending vibrations occur at lower frequencies 
than corresponding stretching vibrations [67].  
 
 
Figure 8| The different vibrational modes of molecules, divided on stretching type (upper line) and on bending 
type (central and lower lines). Adapted from [68]. 
 
Besides the aforesaid vibrations types, interaction between vibrations (coupling) can occur if 
vibrating bonds are joined to a single and central atom. In this turn, vibrational coupling is 
influenced by several factors: 
 Strong coupling of stretching vibrations occurs when there is a common atom between two 
vibrating bonds; 
 Bending vibrations coupling occurs if there is a common bond between vibrating groups; 
 Coupling between a stretching vibration and a bending vibration occurs if the stretching 
bond is one side of an angle varied by bending vibration; 
 Greatest coupling takes place when coupled groups have roughly equal energies; 
 There is no coupling between groups separated by two or more bonds [66].  
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1.3. FTIR equipment and functioning 
There are three basic FTIR spectrometer components: radiation source, interferometer and 
detector. Besides, an FTIR analysis can be divided in 5 steps (Figure 9) [60,61].  
 
Figure 9| Main steps of FTIR process, presenting prime roles of the three basic spectrometer components. 
 
Michelson interferometer (Figure 10) is the most commonly used and it consists of three active 
components: moving mirror, fixed mirror and beamsplitter. These two mirrors are perpendicular to 
each other, while the beamsplitter is a semireflecting device often made by depositing a thin 
germanium film onto a flat KBr substrate. Radiation from the broadband IR source is collimated and 
directed into the interferometer and impinges on the beamsplitter, where half the IR beam is 
transmitted to the fixed mirror and the remaining half is reflected to the moving mirror. After 
reflection of divided beams from the two mirrors, they are recombined at the beamsplitter. 
Source
•IR energy is emitted from a glowing black-body source, often water-cooled for better power
and stability.
•This beam passes through an aperture which controls the energy amount presented to the
sample and, ultimately, to the detector.
Interferometer
•IR beam enters the interferometer, where the "spectral encoding" occurs generating an
interferogram signal with information of every IR frequency that comes from the source.
•It divides radiant beams, generates an optical path difference between beams and then
recombines them in order to produce repetitive interferences signals measured as a function
of optical path difference by the detector.
Sample
•IR beam enters the sample compartment where it is reflected off or transmitted trough the
sample surface, depending of the accomplished analysis.
•Specific energy frequencies, which are uniquely characteristic of the sample, are absorbed.
Detector
•The beam passes to the detector for final measurement of the interferogram signal.
•The two most popular detectors for a FTIR spectrometer are deuterated triglycine sulfate
(DTGS) and mercury cadmium telluride (MCT).
Computer
•The measured signal is digitized and sent to the computer where FT takes place.
•Final FTIR spectrum is presented to the user, available for interpretation and any further
manipulation.
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Changes in the relative position of the moving mirror to the fixed mirror generate an interference 
pattern. The resulting beam then passes through the sample and is eventually focused on detector 
[61].  
 
 
Figure 10|Schematric representation of a FTIR spectrometer, showing their main compartments. BS: 
beamsplitter; X: relative position variation of moving mirror [69].   
 
Since interferogram present every data point, as a time domain spectrum that records detector 
response changes versus time within the mirror scan, all frequencies are measured simultaneously, 
thus resulting in extremely fast IR measurements. This interferogram signal cannot be interpreted 
directly, because it is required a frequency spectrum (plot of intensity at each individual frequency) 
in order to make an identification. Therefore, a mathematical technique called Fourier 
transformation (FT) is performed by the computer so as to “decoding” individual frequencies, 
converting interferogram to the final IR spectrum, which is the familiar frequency domain spectrum 
showing intensity versus frequency [60,61].  
A background spectrum must also be measured, since it is needed to have a relative scale for 
absorption intensity. This is a measurement with no sample in the beam, generating a spectrum 
without any instrumental characteristic. Thus, all present spectral features are strictly due to the 
sample [60].  
1.3.1. Golden Gate™ Diamond ATR 
The technique of attenuated total reflectance (ATR) has been revolutionized solid and liquid sample 
FTIR analyses, since it combats the most challenging aspects of IR analyses, namely sample 
preparation and spectral reproducibility. Besides their complexity, sample preparation methods 
can be very messy, time consuming and further complicated by fragility and hydroscopic nature of 
the involved materials. In turn, ATR requires little or no sample preparation for most samples (high 
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sample throughput). It is especially useful for IR analyses of difficult sample that cannot be readily 
examined by the normal transmission method, being this technique suitable for studying thick or 
highly absorbing solid and liquid materials, including films, coatings, powders, threads, adhesives, 
polymers and aqueous samples. Therefore, ATR technique provides faster sampling, improves 
sample-to-sample reproducibility and minimize user to user spectral variation [61,70,71].  
An ATR accessory (Figure 11) measures the occurred changes in a totally internally reflected IR 
beam when the beam comes into contact with a sample. The IR beam is directed onto an optically 
dense crystal with high refractive index at a certain angle, and internally reflected through the 
crystal with a single or multiple reflections, with both reflections number and penetration depth 
decrease with increasing incidence angle. This internal reflectance creates an evanescent wave that 
extends a few microns (0,5μ– 5μ) beyond the crystal surface into the sample held in contact with 
crystal (Figure 11). In regions of IR spectrum where the sample absorbs energy, the evanescent 
wave will be attenuated or altered, with attenuated energy of each wave being passed back to the 
IR beam, which then exits the opposite end of crystal and is passed to the spectrometer detector. 
Thus, for this technique to be successful, it is required a direct contact between sample and ATR 
crystal, and that crystal refractive index is significantly greater than that of the sample or else 
internal reflectance will not occur – the light will be transmitted rather than internally reflected in 
the crystal [61,70].  
There are several crystal materials available for ATR, with zinc selenide (ZnSe) and germanium being 
the most common used for HATR (horizontal ATR, in which the crystal is a parallel-sided plate, 
typically about 5 cm by 1 cm, with the upper surface exposed). Nevertheless, diamond is by far the 
best ATR crystal material because of its robustness and durability [70].  
 
Figure 11|Golden Gate™ Diamond ATR instrument, showing its single internal reflection system (central and 
right picture). Note the evanescent wave formation under the diamond crystal (right picture). Adapted from 
[70,71]. 
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In liquids analyses, after cleaning the crystal and collecting an IR background, sample is simply 
poured onto the crystal, which must be whole covered if performing a quantitative or qualitative 
analysis. Crystal is recessed into the metal plate to retain sample [70].  
ATR improved spectral acquisition and reproducibility leads to better quality database building, for 
more precise material verification and identification. This makes of ATR an extremely robust and 
reliable technique for quantitative studies involving liquids. Besides it is one of the most versatile 
sampling techniques [61,70].  
 
1.4. FTIR advantages 
Major advantages of FTIR over the traditional dispersive technique include: 
 Speed: since all frequencies are measured simultaneously, it mostly takes seconds (known 
as Felgett Advantage); 
 Sensitivity: dramatically improved with FTIR, since detectors employed are much more 
sensitive and optical throughput is much higher (Jacquinot Advantage), which results in 
lower noise levels; besides fast scans enable coaddition of several scans in order to reduce 
random measurement noise to any desired level (signal averaging); 
 Mechanical Simplicity: the interferometer moving mirror is the only continuously moving 
part in FTIR instrument, so there is little possibility of mechanical breakdown; 
 Internally Calibrated: FTIR instruments employ a HeNe laser as an internal wavelength 
calibration standard (Connes Advantages), which make them self-calibrating [60]. 
 
1.5. MIR spectroscopy applied to biological samples 
Clinical and diagnostic applications of MIR spectroscopy have been one of the most active areas of 
research and development since the 1990s [72]. IR spectra of cells, tissues and biofluids are the sum 
expression of cellular chemistry/biochemistry and give a snapshot on cell division, differentiation, 
growth and metabolism. Besides physiological characterization, IR spectra may report the response 
of biological entities to environmental stress, which makes of biological IR spectroscopy a 
"phenotypic" and explorative analysis modality that can be used into diagnoses of disease or 
dysfunction in cells, tissues and biofluids via "spectral fingerprints". It also may change in response 
to drug intervention, environmental stress or genetic modifications [73].  
Biological fluids such as plasma, serum, synovial fluid and amniotic fluid, are routinely analysed in 
clinical chemistry since these fluids can easily be isolated from the body [73].  
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1.5.1. FTIR at blood-based samples analysis 
FTIR plays critical role at diagnosing and monitoring a wide variety of disorders. The classification 
of disease-related spectral pattern has also been called "diagnostic pattern recognition" (DPR), 
whose concept has been successfully applied in the last decade to establish diagnostic MIR based 
blood analysis, or serum assays for diagnosis of DM, metabolic syndrome, rheumatoid arthritis and 
transmissible spongiform encephalopathies [62,73]. It was already well demonstrated how the 
information-rich MIR spectra may be used to estimate clinically important blood analytes such as 
glucose, proteins, cholesterol, urea, triglycerides, and uric acid when measured in plasma [74]. 
Since each biomolecule exhibit a unique FTIR spectrum, representing the vibrations of its structural 
bonds, a plasma FTIR spectrum exhibit absorption peaks related to its major components [62,74]. 
Proteins are the major component of plasma, with albumin representing 65% of plasma proteins 
and 45% of total plasma mass. The spectral contribution of albumin (4000 – 500 cm-1) represents 
39,9% of total plasma FTIR spectral area. Thus, it is not surprising that after spectra subtraction of 
20 biomolecules, the mean total spectral area of the remaining spectrum corresponds to 24,2% of 
the initial plasma FTIR spectral area. Indeed, in the FTIR spectra of complex biological samples such 
as plasma, the absorption spectra of the more abundant biomolecules may first be subtracted to 
uncover other absorption patterns [75]. Nevertheless, since that in the present study it is used a 
metabolomics approach, this subtraction method could eventually lead to a significant signal loss, 
especially of some lower weight metabolites, and thus it will not be applied in the current study.    
In order to obtain plasma, an anticoagulant like EDTA or heparin is added to full blood previous 
collected, following by removal of blood cells. There is a good reproducibility of metabolite 
concentrations in plasma, which may result from the simple collecting procedure for plasma, as it 
does not require time to coagulate [76]. Removal of cellular component from blood, in order to 
obtain plasma, allows to exclude perturbations of the chemical analysis or to ensure that blood cells 
metabolism does not falsify metabolite concentration values. This latter point is particularly 
important for glucose identification, since its concentration begins to decrease immediately after 
sampling because of the glycolytic action of erythrocytes and leucocytes [77].  
It is important to note that water is the most abundant compound of all biological fluids, which is 
reflected in IR spectra [62]. Following in this chapter some methodologies are presented in order 
to circumvent this water signal overlap within IR spectra.  
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2. FTIR EXPERIMENTAL OPTIMIZATION  
FTIR acquisition methodology has been already optimized in a pilot exploratory study occurred last 
year [78]. Thus, at the present study it was implemented the same optimized methodology. 
 
2.1. Sample collection 
In order to optimize acquisition methodology and to overcome water signals overlap, it was used a 
blood sample from an apparently healthy elderly that belongs to a project approved by ethics 
committee of the Regional Health Centre - Coimbra, protocol number 012 804 of April 4, 2012.  All 
blood samples of this project were received in proper time after its collection, and pre-processing 
was performed immediately [78].  
From each sample were prepared plasma aliquots: it was used tubes K2 EDTA 5 mL with gel 
separator and then it was applied a centrifugal force of 1800g during 15 minutes at 8ºC, wherein 
blood cells were separated from plasma. The obtained plasma was transferred and resuspended in 
a 5 mL tube. For the present study, were performed plasma aliquots of 30 μL, which were stored at 
-80ºC [78]. 
 
2.2. FTIR spectral acquisition 
Plasma samples were thawed at room temperature and homogenized with vortex for around 8 
seconds, immediately before spectroscopic analysis. Spectra were acquired with Perkin-Elmer 
Spectrum BX FT-IR™ spectrometer in the range of 4000-600 cm-1, at resolution of 8 cm-1, with 64 
co-added scans. During acquisition, room temperature and humidity were kept at ± 23ºC and ± 
39%, respectively.  
For spectral acquisition using drying process the attainment of background single beam was 
performed against air (empty crystal). Then, 8 μL of plasma were placed on the ATR diamond 
crystal. Drying time was achieved and established after approximately 40 minutes, which 
corresponds to 16 consecutive spectra acquisition.  
2.2.1. Drying process 
It was demonstrated, for each sample, that 40 minutes of drying time allows to obtain a spectrum 
with more spectroscopic information and enhanced signal-to-noise ratio (SNR) whose peaks can be 
assigned, enabling a qualitative analysis of the sample. It was additionally made a comparison of 
different methods for minimize water signals of samples, included drying process, arithmetic 
subtraction of water spectrum to the plasma spectra, and a third method that uses pure water in 
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the background single beam acquisition which is later used to make the ratio with sample single 
beam. Apart from the apparent less subjectivity, drying process, even time consuming, requires less 
computational manipulations and was shown to be capable of eliminate water spectral 
contribution, maintaining a reasonable SNR [78].  
Thus, by simply allowing water to evaporate from the sample, while spectra are being acquired, it 
is possible observe alterations in spectroscopic signals over time, ensuring that the last spectrum 
obtained reached a constant drying stage. This information is not available by a single spectrum 
acquisition of the film at the end of drying process [78]. 
Therefore, drying process was the chosen method for samples acquisition spectra, which are 
analysed in the follow chapter.  
  
CHAPTER 3  
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1. METHODS OF STUDY 
1.1. Study group 
Inclusion criteria for the present study group were: age between 50-90 years, resident in Aveiro 
region, with complaints including objective memory impairment or other cognitive complains. In 
other hand, exclusion criteria comprise individuals undergoing chemotherapy or radiotherapy, 
suffering from psychiatric illness (e.g. bipolar disease, schizophrenia), or using illicit drugs.  
Cognitive evaluation of individuals was carried out at several centres for primary health care from 
Aveiro region, with application of the following cognitive tests: CDR, MMSE and Geriatric 
Depression Scale (GDS). This latter test allowed exclusion from the study of depressed individuals.  
The project was approved by the ethics committee of the Regional Health Centre - Coimbra, 
protocol number 012 804 of April 4, 2012.   
According to cognitive evaluation, 45 individuals were subdivided in 3 groups: the age and sex 
matched control group, presenting negative result for all the 3 cognitive tests; the putative AD 
group, with a positive result for CDR and MMSE scales but negative for GDS and other 
neuropathologies; the other neuropathologies group, which includes subjects suffering from other 
pathologies or mixed disorder and thus also positive on CDR and MMSE scales. It was also reunited 
other clinical data related to presence of some AD risk factors, namely the manifestation of 
comorbidities such as DM, dyslipidaemia or hypertension (HTN).  
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Table 11| Characterization of study samples group according to sex, age and cognitive evaluation.  
Sex Age Condition MMSE CDR Sex Age Condition MMSE CDR 
F 65 Control - - F 79 Control - - 
F 81 Control - - F 72 Control - - 
F 78 Control - - M 80 AD + - 
F 65 Control - - F 65 AD + - 
F 72 Control - - F 84 AD + + 
F 72 Control - - F 74 AD + + 
F 78 Control - - F 49 AD + + 
F 73 Control - - M 83 AD + + 
M 82 Control - - F 74 AD + + 
F 81 Control - - F 72 AD + + 
M 74 Control - - M 74 AD + + 
F 49 Control - - F 78 AD + + 
F 75 Control - - F 85 AD + + 
F 84 Control - - F 78 AD + + 
F 75 Control - - F 76 AD + + 
M 78 Control - - F 82 AD + + 
F 75 Control - - F 86 AD + + 
F 72 Control - - M 80 AD + - 
F 77 Control - - F 88 AD + + 
F 75 Control - - F 80 AD + + 
M 81 Control - - F 76 Other/mixed dementia + + 
M 82 Control - - F 76 Other/mixed dementia  + + 
F 80 Control - -           
 
1.2. Experimental procedure from blood collection to final results 
The blood collection and plasma sample preparation followed the procedure stated in the previous 
chapter, with application of optimized method for FTIR applied to plasma samples. The spectra 
were obtained by mid infrared spectroscopy (MIR), being recorded a total of three independent 
aliquots (replicates) for each sample, and with the spectrometer diamond crystal being carefully 
cleaned with distilled water between all replicates analyses. This is important for increase 
confidence of obtained results. Room temperature and humidity values were always controlled and 
spectra were only acquired when these room conditions were fulfilled.  
After spectra acquisition, data underwent multivariate analysis to allow differentiate between 
disease and control samples, with identification of relevant spectra regions/bands and their 
corresponding assignments to chemical functional groups and/or compounds families.  
 
1.3. Multivariate data analysis 
Apart from several analytical procedures that result in quantitative data, for diagnostic purposes it 
is important to define some categorical differentiable classes for the obtained data, most 
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commonly by dividing samples in healthy or disease affected classes. This important area of 
chemometric data processing is called classification, whose main aims are pattern recognition and 
discrimination analysis. Univariate analysis methods can consider only a single characteristic of the 
sample as the dependent variable is in a selected given independent variable. Thus, it is usually 
necessary to use multivariate pattern recognition methodologies, which allows the evaluation of 
several sample properties simultaneously [79]. Multivariate analysis uses mathematical, statistical 
and computer sciences to efficiently extract useful information from data generated via chemical 
measurements [80].     
Multivariate classification techniques can be further divided into two categories: unsupervised and 
supervised learning procedures. In this first category, it is not required an a priori knowledge about 
training set samples (i.e. the class membership of the training samples), therefore, samples will be 
grouped into a number of classes with certain communalities without initial qualification of samples 
and their class assignment. Thereby, even without initial knowledge about the expected 
differences, structure with certain data sets may be recognized. Examples of unsupervised methods 
are principal component analysis (PCA) and cluster analysis (CA). In the other hand, supervised 
pattern recognition requires a priori knowledge about the classes contained within the training 
samples, i.e. which sample belongs to which class (e.g. clearly identifying samples from disease 
cases vs. samples from healthy subjects). Examples of supervised methods are discriminant analysis 
(DA) and artificial neural network (ANN) [80, 81]. 
Hence, unsupervised patter-recognition techniques are exploratory methods for data analysis, 
which seek inherent similarities of data. Using this method, unexpected grouping within a training 
sample set that might not be initially evident may be discovered then, e.g. that a group of disease 
samples might be additionally separated into two or more distinctly different classes [80].   
 
1.4. Main MIR regions of interest for study aims 
For biological applications, the MIR region can be divided into spectral windows of interest where 
strong absorption bands can be directly related to specific components (Figure 12). These spectral 
regions include: fatty acids region; amide region, ascribed primarily to proteins and peptides; mixed 
region, ascribed to carboxylic groups of proteins, free amino acids and polysaccharides; and the 
polysaccharide region. Besides, there are others spectral regions such as the one that is relevant to 
RNA, DNA and phospholipid content [82].     
The 900-600 cm-1 region exhibits a variety of weak but extremely characteristic features 
superimposed on an underlying broad spectral contour. This region may contain weakly expressed 
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bands arising from aromatic ring vibrations of phenylalanine, tyrosine, tryptophan, and the various 
nucleotides. Hence valid assignments can hardly to achieve, with the exception of only a few peaks 
(e.g. a band near 720 cm-1, resulting from CH2 rocking modes of fatty-acid chains), this spectral 
domain can be named as to the “true fingerprint region” [83].  
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 Figure 12| Main regions of FTIR spectra in a range of 4000 – 600 cm-1. The mixed region refers to oligosaccharides, free amino acids and nucleic acids. Str: stretching 
 
  58  
 
  
 
  59  
 
2. RESULTS AND DISCUSSION 
2.1. Spectral analysis 
At this section the obtained spectra is subject of direct analysis with observation of general 
vibrational/chemical pattern of whole plasma samples (Figure 13), and identification of main 
maximum wavenumber peaks of the average control and disease samples (Figure 14).  
 
Figure 13| FTIR spectra of all plasma samples that have been used in the present study, in a wavenumber 
range of 4000 – 600 cm-1. The FTIR spectra region of 1800-900 cm-1 has been magnified (down side) for better 
visualization. X-axis: wavenumber (cm-1); Y-axis: arbitrary units (A.U.)   
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Figure 14|The 4000-600 cm-1 FTIR spectral region of two average plasma samples, one of a control subject 
(black line) and other of an AD subject (grey line), showing maximum wavenumber peaks. The downer picture 
is a magnification of the 1800-900 cm-1 FTIR spectra region acquired from the first spectra, showing maximum 
wavenumber peaks. X-axis: wavenumber (cm-1); Y-axis: arbitrary units (A.U.)   
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During direct analysis of FTIR spectra (Figure 14), it was possible to identify the maximum 
wavenumber peaks at both control and disease samples. Each of these spectral signals have one or 
more assignment (specific type of molecular vibration), that corresponds to a certain chemical 
group and/or chemical family of compounds. This correspondence allows to establish a specific 
chemical pattern of plasma samples, with identification of the main chemical components (Table 
12).    
 
Table 12| Maximum wavenumber peaks founded in FTIR spectra and its main assignments and 
correspondents plasma contents. 
Peaks 
(cm-1) 
Assignments Plasma contents Ref. 
≈ 3718 O-H stretching and an intermolecular  
vibration of CO2 and phenol** 
Presence of gaseous CO2  [84] 
≈ 3454 N-H stretching Proteins (amide A) [85] 
≈ 3286 N-H stretching, H-O-H symmetric and 
asymmetric stretching*  
Proteins (amide A) [86,87] 
≈ 3190 N-H symmetric stretching mainly cis-ordered sub-structures [88] 
≈ 3052 N-H stretching Proteins (amide B) [88] 
≈ 2962 C-H asymmetric stretching of CH3 
group* 
Lipid acyl chains in lipid bilayers 
(phospholipids) 
[82,83,86,89] 
≈ 2938 C-H stretching of CH2 and CH3 group* Fatty acids [83,85,86] 
≈ 2878 C-H symmetric stretching of CH3 group* Lipid acyl chains in lipid bilayers 
(phospholipids) 
[82,83,86,89] 
≈ 1740 C=O stretching Fatty acid esters (triglycerides), 
lipid bilayers (phospholipids) 
[79,82,86] 
≈ 1716 C=O stretching Carbonic acid, phospholipid sub-
structures, purine bases from 
nucleic acids 
[79,83,86,90] 
≈ 1638 C=O stretching*;  
NH3+ asymmetric in plane bending 
(rocking)* 
Proteins (amide I for β-sheet); 
Membrane lipids (phospholipids) 
[83,86,89,91] 
≈ 1536 N-H bending in plane, C-N stretching* Proteins (amide II) [83,86,87] 
≈ 1512 CC (phenyl ring) stretching, CH in plane 
bending*  
tyrosine band (proteins side 
chain)  
[83,86,92] 
≈ 1470 CH2 bending;  
C-H asymmetric bending;  
CH2 symmetric in plane bending 
(scissoring)* 
Proteins; 
Carbohydrates;  
Lipid acyl chains in lipid bilayers 
(phospholipids) 
[79,83,88,89] 
≈ 1452 CH2 bending and CH3 asymmetric in 
plane bending (rocking)*; 
C-O symmetric stretching 
Proteins, membrane lipids 
(phospholipids); 
Carbohydrates 
[79,82,88,89] 
≈ 1398 C=O symmetric stretching of COO- 
group, C-O symmetric stretching*; 
C-O bending (carboxylate ions)*; 
CH3 and N+(CH3)3 symmetric bending* 
Proteins and carbohydrates; 
Mixed region (carboxylic groups); 
Membrane lipids (phospholipids) 
[79,82,87,89] 
≈ 1338 CH2 wagging*  Membrane lipids (phospholipids) [87,89] 
≈ 1320 C-O stretching Carbohydrates [79] 
≈ 1290 N-H bending in plane, C-N stretching*; Proteins (amide III); [79,86–88] 
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C-O stretching; 
N-H thymine/cytosine deformation 
Carbohydrates; 
Nucleic acids  
≈ 1242 N-H bending in plane, C-N stretching*; 
P=O asymmetric stretching of PO2- group 
Proteins (amide III, mainly α-helix 
conformation); 
Phosphodiester groups of nucleic 
acids 
[86–88] 
≈ 1168 Ester and CO-O-C antisymmetric 
stretching*;  
C-O, C-C stretching and C-O-H, C-O-C 
deformation* 
Membrane lipids (phospholipids); 
Carbohydrates 
[86,87,89] 
≈ 1115 C-O, C-C stretching, C-O-H, C-O-C 
deformation and C-O-C asymmetric 
stretching*; 
P-O-C symmetric stretching, C-O 
stretching of C-OH group 
Carbohydrates;  
Phosphodiesters, RNA 
[79,86,88] 
≈ 1077 C-O, C-C stretching, C-O-H, C-O-C 
deformation and C-O-C asymmetric 
stretching*; 
PO2-, CO-O-C symmetric stretching*; 
Carbohydrates; 
Membrane lipids (phospholipids) 
and nucleic acids sugar backbone  
 
[79,86,88,89] 
≈ 1032 C-O, C-C stretching, C-O-H, C-O-C 
deformation*; 
C-O symmetric stretching 
Carbohydrates; 
Nucleic acids sugar backbone 
[79,86,88] 
≈ 987 C-O, C-C stretching, C-O-H, C-O-C 
deformation, C-H bending*; 
CH3-N asymmetric stretching 
Carbohydrates; 
Membrane lipids (phospholipids) 
[79,86] 
≈ 924 C-O, C-C stretching, C-O-H, C-O-C 
deformation*; 
N+(CH3)3 symmetric stretching*  
Carbohydrates; 
Membrane lipids (phospholipids) 
[86,89] 
*Characteristic band assignments of biological samples (not specific for plasma) 
**Not characteristic of biological samples 
 
The spectral band at 3718 cm-1 might be related to a higher level of plasma acidity, which is usually 
found at perturbations of acid/base blood balance mechanisms that in turn might be associated to 
presence of general oxidative stress responses. Indeed, in acidic conditions such as generated by 
brain ischemia and hypoxia, especially related to hyperglycaemia as in DM, I2 PP2A (inhibitor-2 of 
protein phosphatase-2A) is cleaved into  a C-terminal and an N-terminal fragments that are known 
to bind to PP2A (protein phosphatase-2A) catalytic subunit inhibiting its activity. Since it has been 
suggested that a decrease in PP2A is a cause of the protein tau abnormal hyperphosphorylation in 
AD, it might be possible the involvement of brain acidosis in AD pathogenesis [93].    
The peptide bond could exhibit nine characteristic IR-active amide bands (A, B and I-VII). 
Nonetheless, at the present study only amide A, B and I-III were identified in FTIR spectrum.  The 
N-H stretching vibration gives rise to the amide A band between 3310 and 3270 cm-1, it is exclusively 
localized on the NH group and is therefore insensitive to the conformation of polypeptide 
backbone, nevertheless its frequency depends on the strength of the hydrogen bond. The amide A 
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band is usually part of a Fermi resonance doublet with the second component absorbing weakly 
between 3100 and 3030 cm-1 (amide B) [85,87,94]. This resonance doublet originates between the 
first overtone of amide II and the N-H stretching vibration. Amides I and II, as mentioned below 
(2.2.2), are the major bands in the protein FTIR spectrum, with amide I providing the most insight 
into secondary structure. Amides III and IV are very complex bands resulting from mixtures of 
several coordinate displacements. Out-of-plane motions could be found in amides V, VI and VII. 
Given the technical and theoretical limitations, only amide bands I, II and III are used for analysis of 
protein secondary structure [85,87].  
It is believed that under oxidative stress and low anti-oxidant defence condition, as appear to occur 
in neurodegenerative disorders, there is a significant lipid damage in the brain tissues, where lipids 
have an important role in modifying the structure, fluidity and function of cellular and subcellular 
membranes. In FTIR spectrum, lipids have characteristic C-H stretching vibrations between 3025 
and 2700 cm-1. Specifically, the long hydrocarbon chains in lipids yield intense asymmetric and 
symmetric C-H stretching vibrations from the aliphatic –CH2 functional group, which fall at ≈2920 
and 2850 cm-1, respectively. For -CH3 functional groups, the asymmetric and symmetric C-H 
stretching modes are found at ≈ 2957 and 2872 cm-1, respectively. In addition, unsaturated olefinic 
C=C-H stretching vibration has a unique vibrational frequency of 3012 cm-1, which is well 
distinguishable from the saturated aliphatic peaks. Thus, the unsaturated lipid content (e.g. PUFAs), 
which is highly vulnerable to oxidative attack given its fullness in double bonds, could be monitored 
by using this olefinic C=C-H stretching mode [90,95].  
The presence of a carbonyl group in a compound can be identified by the strong IR band at the 
region 1650-1850 cm-1, which corresponds to the C=O stretching vibration. At the present study, 
FTIR spectra analysis reveals some peaks in this region (1740, 1716 and 1638 cm-1), which might be 
related to lipid hyperoxidation, especially 1740 cm-1 band. As result of lipid peroxidation, which 
begins with a free radical attack to polyunsaturated lipids, reactive carbonyls are generated. 
Reactive carbonyls are known to influence protein function by alkylation and crosslinking, 
contributing to mitochondrial dysfunction and disrupting of cell cytoskeleton. Furthermore, they 
have been implicated in neurodegenerative disease as intermediates in toxicity [96–98]. Indeed, 
the 1638 cm-1 band corresponds to β-sheet of amide I, which can be related to conformational 
changes of protein α-helices. Since protein secondary structure is stabilized by hydrogen bonding 
of peptide backbone, the exposure of proteins to free radicals provokes damage of hydrogen bonds, 
thus the chains opens and are more prone to free radicals injury, leading to the aforesaid structural 
changes [96].  
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Of the aromatic side chains, tyrosine (Tyr) has been most intensely studied due to its interesting 
properties: it may take part in proton and electron transfer reactions. Tyrosine is a relative strong 
infrared absorber due to its polar character and the ring mode near 1517 cm-1 is one of its most 
intensive bands [92].  
FTIR also provides information about nucleic acid biochemistry, being the more characteristic 
spectra findings of nucleic acids the C=O stretching vibrations from the purine (1717 cm-1) and 
pyrimidine (1666 cm-1) bases, besides antisymmetric (1224 cm-1) and symmetric (1087 cm-1) PO2- 
stretching vibrations at the 1500-1000 cm-1 region [90].   
Besides secondary structure information, some details of protein tertiary structure may also 
appeared to change in AD at the 780-739 cm-1 spectral range [99]. However, it was not possible to 
identify significant maximum peaks in this spectral range.  
At a first glance in Figure 14, it is not possible to achieve and identify significant differences between 
control and disease samples. Therefore, as it will be presented next, PCA methodology was applied 
to data allowing a better comparison between samples and its characterization.  
 
2.2. PCA analysis and identification of main sample groups 
With PCA methodology and analysis of both scores and loadings of profile, it was possible to identify 
and characterize different sub-groups of sample, within control and AD major groups. The spectral 
regions with assignments suggestive of biochemical alterations (Table 12) were submitted to PCA 
analysis.  
2.2.1. Spectral range of 3500-2700 cm-1 
This spectral range is related to the presence of lipids (e.g. saturated or unsaturated), especially 
fatty acids and phospholipids, and its implications for cognitive health and dementia states. Besides, 
some information of amide A and B regions of proteins could be found in this range.  
 
 
 
 
 
 
  65  
 
 
Figure 15| PCA scores of 3500-2700 cm-1 spectral region showing spread of samples at a PC1 x PC2 scores 
diagram. It is possible to identify three distinct groups of samples: cognitive impairment groups (gAD1 and 
gAD2) and control group (gC). C: control samples; D: dementia/cognitive impairment samples 
 
 
 
Figure 16| PCA loadings of 3500-2700 cm-1 spectral region showing the main maximum wavenumber peaks. 
 
 
By analysis of Figure 15 it is possible to achieve that although there are control samples present in 
all quadrant scores the great part of them are distributed among positive PC1 (Q1/Q4). In the other 
hand, despite the fact of disease samples are present in all quadrants, they are mainly concentrated 
in negative PC1 (Q2/Q3), where they also appear to have a more distinct pattern between them.  
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Indeed, PCA loadings analysis turns possible to divide disease samples into two distinct groups, 
according to the presence of different kinds of molecular alterations (Table 13). Besides, disease 
samples present at positive PC1 (Q1/Q4) express a more disperse distribution among control 
samples group.  
It is important to note that the obtained biochemical data cannot be only related to 
absence/presence of dementia, since it might be influenced by other relevant factors, such as the 
presence of comorbidities, disorder of mixed nature, medication, or even factors as age or sex of 
the subjects.       
 
Table 13| Assignments of the main maximum peaks from PCA loadings (range of 3500-2700 cm-1). 
Peak  
(cm-1) 
PCs Assignment 
Score 
(group) 
Ref. 
3400 PC1 (+) N-H stretching of amide A gC [87] 
3286 
PC1 (-) 
PC2 (+) 
N-H stretching of amide A gAD1 [86] 
3172 
PC1 (-) 
PC2 (-) 
O-H stretching band of carboxylic acids gAD2 [68] 
3070 N-H stretching of amide B gAD2 [90] 
3026 N-H stretching of amide B gAD2 [83] 
2952 
PC1 (-) 
PC2 (+) 
C-H asymmetric stretching of -CH3 (fatty acids) gAD1 [68,82,100] 
2926 C-H asymmetric stretching of -CH2 (fatty acids) gAD1 [68,82,87] 
2884 C-H asymmetric stretching of -CH2 (membrane lipids) gAD1 [89] 
2864 C-H symmetric stretching of -CH3 (membrane fatty acids) gAD1 [68,82,89] 
2850 C-H symmetric stretching of -CH2 (membrane fatty acids) gAD1 [82,89,100] 
 
The spectral region 4000-3100 cm-1 is dominated by rather broad spectral features resulting from 
O-H stretching modes (≈3400 cm-1) and from N-H stretching vibrations (amide A and amide B). The 
region between 3100 and 2800 cm-1 presents C-H stretching vibrations of –CH3 and –CH2 functional 
groups and, hence, it is generally dominated by fatty acids of the several membrane amphiphiles 
(e.g. phospholipids) and by some amino acid side-chain vibrations. Complementary information can 
be deduced from the spectral region 1470-1400 cm-1, where the various deformation modes of 
these functional groups are present [83].  
 
Group AD1: cognitive impairment with altered metabolism of lipids 
As aforesaid, the unsaturated lipid content (e.g. PUFAs) could be monitored by using the olefinic 
C=C-H stretching mode at the frequency of 3012 cm-1, whose intensity is proportional to the amount 
of unsaturated lipid in the analysed tissue. At healthy conditions, PUFAs as part of phospholipid 
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membranes have a key structural role being critical for brain normal function (e.g. membrane 
fluidity, single transduction). It is even believed that these lipids are capable of confer protection 
against amyloidogenesis, since it was already shown in AD transgenic mouse models and cell culture 
experiments that they could diminished amyloid burden, possibly by disruption of amyloidogenic 
pathway and/or increase of Aβ clearance mechanisms [90,95].  
At the current study, it was not possible to identify any peak close to 3012 cm-1, which could indicate 
very low content of unsaturated lipids that makes the signal to much weak for being detected. 
Significant low levels of PUFAs in brain tissue are usually related to AD condition, being a possible 
evidence of lipid peroxidation with presence of protein carbonyl formation and high content of lipid 
peroxidation products. This may translate in a higher risk and severity of AD, with progression of 
amyloidogenesis. It is thought that these events take place in an early stage of amyloid plaques 
formation [95].  
Moreover, frequency changes in the spectral range 3025-2800 cm-1, especially CH2 stretching 
vibrations, can be used as a marker of alterations in the lipid order of the biological system. Indeed, 
it was possible to identify several peaks in this region (i.e. 2952 cm-1, 2926 cm-1, 2884 cm-1, 2864 
cm-1 and 2850 cm-1), all of them are related to the presence of saturated lipids. In addition to the 
absence of unsaturated content spectra signal, this means that there is an unbalance between the 
content of saturated and unsaturated lipids, favouring the first one. Besides the aforesaid potential 
brain damage, a high content of saturated lipids is related to vascular disturbances and atherogenic 
processes, which translates in higher risk for cerebrovascular occurrences leading to ischemia and 
oxidative stress events. This kind of vascular perturbations are strong correlated with higher risk of 
dementia development [68,89,90,96].  
 
Group AD2: cognitive impairment with changes in protein conformation  
These group are mainly characterized by the presence of carboxylic acids, related to strong O-H 
stretching vibrations at 3172 cm-1.  As mentioned above, this kind of compounds are usually related 
to lipid hyperoxidation, production of reactive carbonyls and protein structural and functional 
disturbances, being implicated in the neurodegeneration process. Therefore, the presence of these 
carboxylic compounds might be related to the changes in protein conformation that can be verify 
trough 3070 cm-1 peak, which translates in a modified localization of amide B region [68,90,96,97] 
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Group C: control samples  
This group is mainly constituted by control samples that appear to have a biochemical pattern 
without any issues that might be related to neurodegeneration process, being characterised by the 
presence of assignment for amide A related to the peak 3400 cm-1, a common band found at 
proteins spectra [87]. Besides, there are also present inside its frontiers some dispersed disease 
samples, which have less contribute from negative PC1 related peaks.  
Giving the presence of some controls at negative PC1, this might be associated to the fact that these 
samples could present similar biochemical pattern to the respective disease samples that belongs 
to gAD1 and gAD2, which could translate in a higher risk of developing dementia or even the 
presence of cognitive impairment in a pre-clinical stage, and thus not detectable by cognitive tests.   
  
2.2.2. Spectral range of 1700-1400 cm-1  
As already presented above, this spectral range corresponds mainly to protein conformation mode 
trough analysis of protein secondary structure (amide I and II), although it might be related also to 
chemical properties of nucleic acids bases, fatty acids and carbohydrates.  
 
 
Figure 17| PCA scores of 1700-1400 cm-1 spectral region showing spread of samples at a PC2 x PC3 scores 
diagram. It is possible to identify three distinct groups of samples: cognitive impairment one (gAD) and control 
groups (gCA and gCB). Samples D11 and C1 as potential outliers. C: control samples; D: dementia/cognitive 
impairment samples 
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Figure 18| PCA loadings of 1700-1400 cm-1 spectral region showing the main maximum wavenumber peaks. 
 
 
Trough analysis of Figure 17 is possible to verify that there is a predominance of dementia subjects 
with negative PC3 value (Q3 and Q4), while majority of control samples presents positive PC3 
(mainly founded at Q2) despite existence of some control subjects at Q4 (negative PC3). This 
distributional pattern of samples, accounting with additional information from PCA loadings (Figure 
18) and additional clinical data, allow to identify three distinct groups of samples: dementia group 
(gAD) and control groups (gCA and gCB). Dementia sample group is localized in negative region of 
PC3, while control sample groups are located in positive PC3 region (gCA and part of gCB) and 
positive PC2 (gCB). It is believed that C1 and D11 samples (signalled by an arrow) appear to be 
outliers given the significant lower age of their subjects, comparably to the others.  
A better characterization of these groups is only possible with analysis of correspondent 
assignments of loadings signals peaks (Table 14).  
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Table 14| Assignments of the main maximum peaks from PCA loadings (range of 1700-1400 cm-1).  
Peak 
(cm-1) 
PCs Assignments 
Scores 
(group) 
Ref. 
1682 PC3 (+) 
C=O guanine deformation N-H in plane; unordered random 
coils, turns and loops (amide I) 
gCB [85,88,101] 
1664 PC2 (+) C=O band of α-helical structure (amide I)*, turns and loops gCB [85,96] 
1650 PC2 (+) 
C=O symmetric stretching band of α-helical structure  
(amide I) 
gCB [86,100] 
1638 PC3 (+) C=O stretching band of parallel β-sheet (amide I) gCB [86] 
1623 PC3 (+) C=O stretching band of parallel β-sheet (amide I) gCB [85,90,101] 
1588 PC3 (-) 
N-H bending in plane and C-N stretching (amide II); benzene 
ring vibrations from arginine  
gAD [68,87,88] 
1582 PC3 (-) 
C=N imidazole ring stretching (nucleic acids); benzene ring 
vibrations from arginine 
gAD [68] 
1576 PC3 (-) 
N-H bending in plane and C-N stretching (amide II); 
NH3+ symmetric bending (membrane lipids);  
C=N imidazole ring stretching (nucleic acids)  
gAD [68,82,89] 
1560 PC2 (+) 
N-H bending in plane and C-N stretching of amino acids  
(amide II); CO2- asymmetric stretching from glutamic acid  
gCB [68,87] 
1554 PC2 (+) 
N-H deformation mode of α-helical band (amide II)*;  
CO2- asymmetric stretching from glutamic acid 
gCB [68,85] 
1542 PC2 (+) 
N-H bending in plane and C-N stretching of amino acids  
(amide II) 
gCB [87,88,100] 
1520 
PC2 (-) 
PC3 (+) 
N-H bending in plane and C-N stretching of amino acids  
(amide II);  
gCA [85,91] 
1510 
PC2 (-) 
PC3 (+) 
N-H bending in plane and C-N stretching of amino acids  
(amide II); C-H in plane bending of phenyl rings (tyrosine) 
gCA [85,91,92] 
1490 
PC2 (-) 
PC3 (+) 
N+(CH3)3 asymmetric bending (membrane lipids)  gCA [68,89] 
1472 
PC2 (-) 
PC3 (+) 
CH2 scissoring of proteins and CH3 scissoring of phospholipids 
(membrane lipids)  
gCA [68,86,89] 
1464 PC3 (-) 
CH2 scissoring and CH3 scissoring and asymmetric bending of 
phospholipids (membrane lipids)  
gAD [68,86,89] 
 1458 PC3 (-) 
C=O symmetric stretching of COO- of amino acid side chains; 
CH2 bending of mainly fatty acids (membrane lipids) 
gAD [89,102] 
1408 PC3 (-) 
C=O symmetric stretching of COO- of amino acid side chains 
and fatty acids; N+(CH3)3 symmetric bending (membrane 
lipids)  
gAD [68,100,102] 
*related to structural analysis of synthetic polypeptides  
 
The typical protein spectrum has two prominent features, amide I (1600-1700 cm-1) and amide II 
(1500-1560 cm-1) bands, where the former arise from the C=O stretching vibration and the latter is 
attributed to the N-H bending and C-N stretching vibrations of peptide backbone. The frequency of 
amide I band is particularly sensitive to secondary structure based on different hydrogen-bonding 
environments for α-helix, β-sheet, turn and unordered conformations. For example, α-helices and 
β-sheets have amide I vibrational frequencies at approximately 1655 and 1630 cm-1, respectively. 
This makes of FTIR a valuable technique for assessing protein aggregation at neurodegenerative 
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disorders. The amide I vibrational frequency of an aggregated protein falls around 1685-1695 and 
1620-1630 cm-1, due to the distinct hydrophobic environment [85,90].  
 
Group AD: cognitive impairment with alterations in lipids and nucleic acids biochemistry 
Oxidative stress and free radical damage have been recognized as important factors in degenerative 
disorders such as AD. Indeed, Aβ can induce free radical formation, which contributes even more 
for the inflammatory mechanisms related AD pathological development. Besides, inflammatory 
proteins are thought to exacerbate AD pathogenic process by stimulating Aβ production, and thus 
facilitating its aggregation in plaques and increasing its neuronal cytotoxicity [90,102].  
Therefore, it is not surprising that there is a decreased intensity of 1455 cm-1 centred peak (Table 
12), which is close to the 1458 cm-1 peak identified at the present study (Figure 18). This results 
from deformation and stretching vibrations of CH2 groups particularly in fatty acids (present in 
membrane lipids) [89,102]. The brain is known to have a high content of easily peroxidizable 
unsaturated fatty acids (especially arachidonic and docosahexaenoic acids) and a high content of 
iron, which are key factors for neuronal membrane lipoperoxidation. Indeed, isoprostanes 
(specifically generated from arachidonic acid) were considered as stable markers of oxidative lipid 
damage in AD patients [102].  
Besides, the 1582 cm-1 band might be associated to alteration of conformational state and 
structural stability of nucleic acid molecules. The same may also be stated for 1576 cm -1, to which 
is added structural changes in lipids. Once again, it could be found in 1588 cm-1 peak a different 
localization for amide II, related to altered protein conformation and presence of protein 
aggregates typical of AD. In other hand, similarly to the aforesaid for 1458 cm-1 peak, 1464 cm-1 and 
1408 cm-1 peaks are due mainly to structural changes of associated membrane lipids, namely fatty 
acids and phospholipids, which are the principal targets of free radicals, oligomers and other 
damage-inducing agents [68,86,87,89].   
Although β-sheet content in oligomers is lower than in fibrils (where this content is about to 75%), 
it is significant and have already shown to reach 48-57% of total oligomer constitution. This lower 
content in secondary protein structure and faster dynamics exchange probably reflects a higher 
flexibility of Aβ in soluble oligomers than in fibrils, which could be related to lower stability and 
higher toxicity of oligomer forms comparatively to fibrils. In fact, it is thought that soluble 
oligomers, also known as protofibrils or ADDLs (Aβ-derived diffusible ligands), may interact with 
cellular lipid bilayers and causing its perturbation and/or permeabilization [103].  
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Indeed, several recent studies in the field of protein-folding diseases suggest that the neuron 
toxicity arises from the initial oligomeric species, rather than the largest protein plaques. The 
mechanism of oligomer toxicity is still under debate, but includes formation of transmembrane 
pores that disrupt ion transport through cells. Pore-forming oligomeric structures have been 
described with Aβ in AD and α-synuclein in Parkinson’s disease [90].  
A previous study was already shown that the spectral region 1480-1428 cm-1 provided the largest 
differentiation between control and disease samples, suggesting that oxidative stress-dependent 
processes in AD lead to modified lipid and nucleic acid structures [90,102].  
Almost all of patients that belongs to AD group present comorbidities, which may be translated in 
higher severity and faster progression of the disease condition. 
 
Patient D5 
The patient D5 are present at both Q1 and Q4 scores, being related to the presence of altered 
protein conformation and cell damage trough oxidative stress, namely membrane lipids and nucleic 
acid molecules. This might be translated into a more advanced and severe stage of disease 
comparably to the reminder patients, or instead it may be possible that this patient suffer from a 
mixed pathology and thus present a different plasma biochemical pattern. D5 shows a positive 
value for MMSE score but a negative one for CDR scale, besides the existence of both DM and HTN 
comorbidities, which enforces the aforesaid picture.    
 
Group CA: pure control subjects 
These control group is a pure one, with all samples inside group borders being controls. Besides,  
this appear to present an unaltered proteins conformation, without any signal that could indicate 
protein aggregation or presence of intermediate damaging forms like oligomers. This is consistent 
with biochemical pattern of a control sample and it is related to 1520 cm-1 and 1510 cm-1 peaks 
[85,91].  
Nevertheless, the other peaks related to CA group (i.e. 1472 cm-1 and 1490 cm-1), are associated to 
structural properties of membrane lipids, and the 1490 cm-1 peak is particularly connected to 
membrane injury probably due to the action of oxidative stress and free radicals inductors of cell 
damage. The brain is particularly vulnerable to oxidative damage (as could be possible of being 
detected trough IR plasma analysis) for reasons already mentioned above, which in addition of the 
diminished oxidative defences characteristically from the normal aging process and the presence 
of comorbidities (i.e. DM and HTN) provides the perfect picture for developing dementia and/or 
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some other related neurodegenerative disorder [68,86,89,104,105]. Indeed, all subjects from CA 
group suffer from comorbidities such as DM and HTN. Given the possibility of these subjects had 
already achieve the pre-MCI or initial phase of MCI state, it would be important theirs clinical 
monitoring.  
 
Group CB: control subjects with potential picture of MCI 
This group comprises control samples dispersed among Q1/Q4 and a small cluster of disease 
samples located in Q1, which are related to changes in protein conformation.  
Giving their coordinates and their match to amide I region of aggregated proteins, peaks present at 
1682 cm-1, 1638 cm-1, 1623 cm-1 could be related to disease samples present among CB group 
(Figure 17). Indeed, 1623 cm-1 peak had been considered as characteristic of a protein in an 
aggregated state, during FTIR analysis of cerebral tissue from AD patients [85,90,101].  
Contrarily to fibrils, oligomers present both 1630 and 1695 cm-1 peaks, which corresponds to an 
anti-parallel β-sheet conformation. This 1695 cm-1 peak is not present in PCA loadings (Figure 18), 
and there is two peaks near to 1630 cm-1 (i.e. 1623 cm-1 and 1638 cm-1), which is related to highly 
stable parallel β-sheet that in turn is usually associated to the presence of fibrils. Since it is believed 
that Aβ soluble oligomers are an intermediate form that precedes Aβ fibrils, it is not difficult to 
believe that a higher proportion of Aβ fibril forms is related to a later stage of the disease. Still, it is 
needed to considerer that the 1695 cm-1 peak signal is five times weaker than the signal related to 
1630 cm-1 peak, and thus, the absence in PCA loadings (Figure 18) of the former peak signal does 
not mean the complete lack of oligomer forms in the analysed samples. Actually, the 1695/1630 
cm-1 intensity ratio is proportional to the percentage of anti-parallel β-sheet content in Aβ 
aggregates. Once again, given the absence of 1695 cm-1 peak, it is suggested that Aβ fibrils are 
present in higher content than Aβ oligomers [103].   
Moreover, it must not be forgotten that most of the proteins present a mixture of secondary 
structures, and thus, the amide I band represents a combination of these components [85,90]. 
Indeed, the 1670-1685 cm-1 region is related to the presence of non-β structure in protein fibrils, 
especially turns and loops. Thus, in addition to the parallel β-sheet core related to 1638 cm-1 and 
1623 cm-1 peaks, Aβ fibrils present in lower content non-β structures related mainly to 1682 cm-1 
band. Besides, amorphous aggregates also may present a spectral band at 1623 cm-1, and they are 
not associated to a higher content of β-sheet structure, contrarily to protein fibrils. Since a 1623 
cm-1 band has been identified (Figure 18), this might indicate that besides protein fibrils there are 
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also some amorphous aggregates, arising from a relatively unfolded-like partially folded and a 
native like conformation, respectively [101].   
Likewise, it was found during analysis of synthetic polypeptides that components of C=O band with 
α and β forms are related to spectral peaks at 1658 cm-1 and 1629 cm-1, respectively. Besides, the 
N-H deformation mode had presented a signal peak at 1550 cm-1, which showed to correspond to 
α form [85]. At the present study, it is possible to find 1664 and 1623 cm-1 peaks related to α and β 
forms, in addition to the identified peaks at 1554 and 1542 cm-1 that are linked to N-H deformation 
mode (Table 14).  
 
In the other hand, control samples could be associated to signal peaks identified at 1664 cm -1 and 
1650 cm-1 that are related to the typical localization of amide I of proteins mainly constituted by α-
helix structures. This is complemented by protein structural information given by 1560 cm -1, 1554 
cm-1, 1542 cm-1 and 1538 cm-1 peaks [85–87,100]. Nevertheless, giving the proximity of these 
samples to the disease ones, from both Q1 (protein aggregates) and Q4 (lipid and nucleic acids 
altered biochemistry), it is possible that control samples share some biochemical characteristics 
with disease samples. Besides, almost all control subjects from CB group (exception for C4) suffer 
from comorbidities such as DM and HTN, which can be translated per se in a higher risk of 
developing some demented disorder comparatively to the average healthy cognitive population 
that not present this kind of comorbidities. Therefore, it is quite plausible that control subjects have 
already been suffering with a pre-clinical form of cognitive impairment (i.e. beginning of MCI).  
 
2.2.3. Spectral range of 1200-900 cm-1 
The spectral region 1200 - 900 cm-1 is usually dominated by the symmetric stretching of PO2 groups 
in nucleic acids and a complex sequence of peaks due mainly to strongly coupled C-C, C-O stretching 
and C-O-H, C-O-C deformation modes of several oligosaccharides [83]. Besides oligosaccharides and 
nucleic acids structural and functional information, it is possible to identify signal peaks related to 
membrane lipids.   
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Figure 19| PCA scores of 1200-900 cm-1 spectral region showing spread of samples at a PC1 x PC2 scores 
diagram. It is possible to identify five distinct groups of samples: cognitive impairment ones (gAD1 and gAD2), 
and control groups (gCA, gCB and gCC). Samples C13 and D14 as potential outliers. C: control samples; D: 
dementia/cognitive impairment samples 
 
 
 
Figure 20| PCA loadings of 1200-900 cm-1 spectral region showing the main maximum wavenumber peaks. 
 
 
Through analysis of Figure 19 it is possible to distinguish disease samples into two well delimited 
groups, with gAD1 at Q2/Q3 and gAD2 at Q1/Q4. In the other hand, control samples are divided 
into three groups, with gCA at Q2/Q3 and inside gAD1 frontiers, gCB at Q1/Q2 and gCC at Q1/Q4. 
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Table 15| Assignments of the main maximum peaks from PCA loadings (range of 1200-900 cm-1). 
Peaks 
(cm-1) 
PCs Assignments 
Score 
(group) 
Ref. 
1168 
PC1 (+) 
C-O stretching of ribose from nucleic acids; CO-O-C 
asymmetric stretching (membrane lipids) 
gAD2 [68,86,89,102] 
1122 
PO stretching of phosphodiester backbone and C-O 
stretching of deoxyribose and ribose (nucleic acids) 
gAD2 [68,102] 
1090 
PO2- symmetric stretching of sugar rings (nucleic acids) 
and membrane lipids 
gAD2 [68,82,89,90] 
1078 
PC1 (-) 
CO-O-C symmetric stretching (membrane lipids) gAD1 [68,89] 
1062 
Ester C-O-C symmetric stretching (phospholipids); ribose 
C-O stretching (nucleic acids) 
gAD1 [68,86] 
1048 C-O stretching of sugar rings (nucleic acids) gAD1 [68,102] 
1034 
C-N symmetric stretching of amino acid (aliphatic 
amines); ribose C-O stretching (RNA) 
gAD1 [68,100] 
1018 
C-O stretching in osidic and protein structures; symmetric 
stretching of dianionic phosphate monoester (nucleic 
acids, especially DNA) 
gAD1 [68,102] 
1002 
C-O stretching in osidic and protein structures; uracil ring 
bending (RNA); symmetric stretching of dianionic 
phosphate monoester (nucleic acids, especially DNA) 
gAD1 [68,102] 
988 
C-O stretching in osidic and protein structures; symmetric 
stretching of dianionic phosphate monoester (nucleic 
acids, especially DNA) 
gAD1 [102] 
974 
C-O stretching in osidic and protein structures; N+(CH3)3 
asymmetric stretching (membrane lipids); symmetric 
stretching of dianionic phosphate monoester (nucleic 
acids, especially DNA) 
gAD1 [68,86,89,102] 
958 
PC1 (+) 
C-O stretching in osidic and protein structures; symmetric 
stretching of dianionic phosphate monoester (nucleic 
acids, especially DNA) 
gAD2 [102] 
930 
C-O-H out of plane bending of carboxylic acids; C-O 
stretching in osidic and protein structures; symmetric 
stretching of dianionic phosphate monoester (nucleic 
acids, especially DNA) 
gAD2 [68,102] 
 
The wavenumber components characteristics of each sample group are difficult to define since all 
these groups are distributed among PC1 region, thus having less contribute from PC2. Therefore, 
the analysis of main maximum peaks presented in PCA loadings (Table 15) does not allow to 
distinguish clearly the biochemical pattern between gAD1 and gAD2, with both presenting 
structural and functional alterations mostly in nucleic acids, but also in membrane lipids and 
proteins. Besides, it is not equally possible to differentiate the three control groups from each other 
through PCA loadings, since it has not been identified spectral bands that could be related to control 
characteristics.  
Nevertheless, according to group’s distribution among PC1 region, gAD1 show to have more 
contribute from negative PC1 signal peaks, while gCC presents more contribution from positive PC1 
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signal peaks. This might indicate that gCC, presented in Figure 19 as a pure control group, have 
opposing biochemical characteristics in relation to gAD1, which could translate in opposing clinical 
profiles. In the other hand, gCB comprises control samples from subjects with some similar 
characteristics, namely sex and age, besides almost all these subjects suffer from vascular 
comorbidities that translates in a higher risk for developing cognitive impairment.  
 
Groups AD1 and AD2: cognitive impairment with lipid and nucleic acids disturbances 
The C-O stretching bands, especially from the 1150-1000 cm-1 spectral region, are related to the 
presence of hydroxyl compounds, which are products of lipid peroxidation and have already been 
reported as markers of oxidative damage in AD [99]. Besides, the 1200-1100 cm-1 region is related 
to the presence of saturated lipids (aliphatic esters), which may be translated into a higher content 
of saturation associated to a higher risk of membrane damage and vascular events. It is already 
known that hyperoxidation of lipids, phospholipids and membranes takes place during the 
atherogenesis process, and since the majority of patients from both gAD1 and gAD2 have 
comorbidities such as DM, HTN or dyslipidaemia, this might confer the risk of a more severe picture 
of neurodegeneration [68,96]. The presence of atheromatous formations in the extracranial and 
intracranial blood vessels predisposes to ischemic events, both subclinical brain infarction and 
stroke, as well as small vessel disease and amyloid angiopathy, provoke white matter damage and 
even cerebral haemorrhagic events. Both cerebral ischemia and haemorrhage are known to 
interact with AD pathology in a bidirectional way. In the same manner, high blood pressure may 
damage small blood vessels, affecting cognition by disruption of subcortical neuronal circuits  [106].  
Nucleic acids molecules, especially DNA, represent a major target for free radicals when capacity of 
intracellular free radical scavengers and antioxidants is overcome, as it is possible to verify trough 
the identified spectral peaks at 1122 cm-1, 1090 cm-1, 1048 cm-1, and the ones that belong to the 
1020-930 cm-1 region. Some studies in vitro have shown that hydroxyl radicals are able to attack 
the deoxyribose moiety, generating a variety of products that result from hydrogen abstractions of 
the pentose ring and provoke loss of phosphoric acid and breaking of strands. Although many repair 
enzymes systems have evolved to remove and replace the damaged nucleosides and repair the 
broken strands, there is a high rate of DNA damage as it was already shown by the high plasmatic 
levels of 8-OHdG (8-hydroxydeoxyguanosine) found in AD patient samples. It is believed that 
cumulative DNA damage contributes to progressive neuronal cell loss because nonrepaired DNA 
damage can trigger programmed cell death [102].  
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3. CONCLUDING REMARKS  
Direct analysis of spectra allowed to identify the main chemical FTIR assignments in plasma, which 
is essential for establish a pattern of chemical vibrations and identify the principal spectral regions 
that could present significant information. However, giving the complexity of biological samples 
and the resultant overlaps of the main biomolecules absorptions, direct analysis of spectra proved 
to be insufficient to distinguish between the spectra of control and dementia samples. Thus, it was 
needed to apply multivariate data analysis methodology, namely PCA technique, to draw out the 
significant and no redundant spectra information.  
Trough multivariate analysis, it was possible to achieve spectrum data with important information 
from the main IR relevant regions, namely from lipids (3500-2700 cm-1), protein conformation 
(1700-1400 cm-1), and also from carbohydrates and nucleic acids structure (1200-900 cm-1). At the 
analysis of the first spectral region, it was noted that in disease samples there is an unbalance 
between the content of saturated and unsaturated lipids, favouring the first one. This translates in 
a high potential brain damage, since a high content of saturated lipids is related to vascular 
disturbances and atherogenic processes, leading to cerebrovascular occurrences and to ischemia 
and oxidative stress events. Hence, it could be shown the presence of carboxylic acids that are 
usually related to lipid hyperoxidation, production of reactive carbonyls and protein structural and 
functional disturbances, being implicated in the neurodegeneration process. Relatively to 1700-
1400 cm-1 spectral range, it was identified the existence of protein aggregates and the change in 
protein conformation for highly stable parallel β-sheet, which is usually associated to the presence 
of Aβ fibrils. Samples D3, D5 and D9 appear to be the ones that most influence these findings. Since 
it is believed that Aβ soluble oligomers are an intermediate form that precedes Aβ fibrils, it is not 
difficult to believe that a higher proportion of Aβ fibril forms is related to a later stage of the disease. 
In 1200-900 cm-1 region, it was possible to find products of lipid peroxidation related to impairment 
of membranes, and nucleic acids oxidative damage. In a previous work involving FTIR analysis of 
plasma samples, it was denoted a higher risk of vascular damage in cognitive impaired subjects, 
besides evidences of potential oxidative stress that are also present in the current project [78].       
Giving the presence of several comorbidities in the majority of subjects, it is possible to suggest that 
vised controls are at higher risk of developing dementia rather than average healthy population, 
and in turn, vised cognitive impaired patients are prone to develop a more insidious and severe 
disorder picture with a faster neurodegeneration process. Moreover, biochemical data that had 
result from this project cannot be only related to absence/presence of dementia, or even to 
occurrence of aforesaid comorbidities, there are also other relevant clinical factors that could 
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influence results, such as the presence of a neurodegenerative disorder of mixed nature, unknown 
and/or undiagnosed genetic predisposed factors, or use of medication capable of affect 
biochemical plasma levels.       
As a final remark, FTIR analysis could have the potential to be applied in future not only for cognitive 
impairment diagnosis but also for identification of disease stage and prognostic evaluation, besides 
assessment of disease developing risk for control subjects. To make it possible it will be required 
further clinical trials with data sets more approximate from general population, besides it will be 
needed a sustainable and efficient validation model to transfer potential biomarkers from these 
clinical trials to clinical practice.     
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